Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

INCY

Incyte Corp

Mar 11 • 04:00PM ET

68.07

Dollar change -3.06
Percentage change -4.30	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN GILD IONS BMY MRK JNJ AMGN PFE LLY

| Held by: VTI VOO RSP VB SPY XBI IVV VO USMV VBK

Index	S&P 500	P/E	251.00	EPS (ttm)	0.27	Insider Own	1.46%	Shs Outstand	193.43M	Perf Week	-2.31%
Market Cap	13.17B	Forward P/E	10.25	EPS next Y	6.64	Insider Trans	-1.65%	Shs Float	190.71M	Perf Month	-8.17%
Income	32.62M	PEG	2.61	EPS next Q	1.01	Inst Own	95.41%	Short Float	3.07%	Perf Quarter	-9.14%
Sales	4.24B	P/S	3.11	EPS this Y	422.92%	Inst Trans	-0.08%	Short Ratio	3.48	Perf Half Y	11.12%
Book/sh	17.82	P/B	3.82	EPS next Y	18.06%	ROA	0.53%	Short Interest	5.85M	Perf Year	15.31%
Cash/sh	11.15	P/C	6.10	EPS next 5Y	96.29%	ROE	0.76%	52W Range	50.35 - 83.95	Perf YTD	-1.45%
Dividend Est.	-	P/FCF	52.89	EPS past 5Y	-40.36%	ROI	0.93%	52W High	-18.92%	Beta	0.84
Dividend TTM	-	Quick Ratio	1.94	Sales past 5Y	14.56%	Gross Margin	91.09%	52W Low	35.19%	ATR (14)	2.42
Dividend Ex-Date	-	Current Ratio	1.97	EPS Y/Y TTM	-88.32%	Oper. Margin	1.89%	RSI (14)	38.27	Volatility	3.86% 3.68%
Employees	2617	Debt/Eq	0.02	Sales Y/Y TTM	14.76%	Profit Margin	0.77%	Recom	2.30	Target Price	77.42
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	14.62%	Payout	0.00%	Rel Volume	0.97	Prev Close	71.13
Sales Surprise	3.39%	EPS Surprise	-5.06%	Sales Q/Q	16.32%	Earnings	Feb 10 BMO	Avg Volume	1.68M	Price	68.07
SMA20	-4.12%	SMA50	-5.04%	SMA200	0.77%	Trades		Volume	1,626,379	Change	-4.30%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-24	Initiated	UBS	Neutral	$77
Oct-29-24	Upgrade	BofA Securities	Neutral → Buy	$68 → $90
Oct-01-24	Initiated	Wolfe Research	Outperform	$84
Sep-18-24	Downgrade	Truist	Buy → Hold	$83 → $74
Jul-02-24	Downgrade	BMO Capital Markets	Market Perform → Underperform	$52 → $48
May-23-24	Initiated	Deutsche Bank	Hold	$55
Apr-23-24	Initiated	Cantor Fitzgerald	Neutral
Feb-23-24	Initiated	Jefferies	Buy	$81
Feb-14-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-13-23	Upgrade	Leerink Partners	Market Perform → Outperform	$78
Dec-04-23	Upgrade	Guggenheim	Neutral → Buy	$86
Nov-21-23	Downgrade	Goldman	Buy → Neutral	$98 → $65
Jul-25-23	Initiated	Citigroup	Buy	$82
May-04-23	Downgrade	BofA Securities	Buy → Neutral	$84
Apr-10-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$81 → $79
Mar-24-23	Upgrade	SVB Securities	Underperform → Market Perform	$61
Jan-31-23	Initiated	Piper Sandler	Overweight	$100
Aug-03-22	Downgrade	Guggenheim	Buy → Neutral
Aug-03-22	Downgrade	Evercore ISI	Outperform → In-line	$90 → $78
Jul-28-22	Initiated	Wells Fargo	Equal Weight	$76

Show Previous Ratings

Mar-11-25 08:48AM	Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss (Benzinga)
Mar-10-25 01:38PM	Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps (Benzinga)
Mar-08-25 01:00PM	Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study (PR Newswire)
09:01AM	Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting (Business Wire)
Mar-07-25 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
02:31PM	Loading…
Mar-01-25 02:31PM	Is Incyte Corporation (INCY) The Best Immunology Stock To Buy Now? (Insider Monkey)
Feb-28-25 09:30AM	Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting (Business Wire)
Feb-25-25 08:53AM	Incyte Corporation (INCY) Partners with Genesis AI to Accelerate Drug Discovery (Insider Monkey)
Feb-21-25 07:20AM	Incyte and Genesis collaborate on small-molecule medicines (Pharmaceutical Technology)
Feb-20-25 08:00AM	Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration (Business Wire)
Feb-18-25 04:16PM	Incyte Stock Sees Relative Strength Rating Rise To 71 (Investor's Business Daily)
08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
03:00AM	Incyte Sees Relative Strength Rating Rise To 71 (Investor's Business Daily)
Feb-11-25 05:55PM	Analyst Report: Incyte Corporation (Morningstar Research)
02:04AM	Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook (GuruFocus.com)
11:28PM	Loading…
Feb-10-25 11:28PM	Q4 2024 Incyte Corp Earnings Call (Thomson Reuters StreetEvents) -7.86%
05:27PM	S&P 500 Gains and Losses Today: Supermicro Stock Surges Ahead of Business Update (Investopedia)
04:43PM	Incyte Reports 2024 Financial Results and Outlines 2025 Projections (GuruFocus.com)
02:56PM	Why Incyte (INCY) Shares Are Plunging Today (StockStory)
02:47PM	Incyte Stock Sinks as Sales Forecast for Key Drugs Falls Short (Investopedia)
10:38AM	Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches (Benzinga)
09:30AM	Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:15AM	Incyte (INCY) Q4 Earnings Miss Estimates (Zacks)
07:30AM	Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4 (StockStory)
07:23AM	Incyte: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones (Business Wire)
Feb-09-25 08:02AM	Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow (StockStory)
Feb-07-25 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.86%
Feb-05-25 09:15AM	Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Feb-03-25 10:00AM	Incyte (INCY) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	Loading…
Jan-21-25 08:00AM	Incyte to Report Fourth Quarter and Year-End 2024 Financial Results (Business Wire)
Jan-15-25 05:34PM	Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes (PR Newswire)
08:54AM	JP Morgan 2025: Incyte expects period of defining catalysts (Pharmaceutical Technology)
Jan-13-25 09:40AM	Has Incyte (INCY) Outpaced Other Medical Stocks This Year? (Zacks)
08:30AM	Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-08-25 06:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-20-24 07:20AM	Incyte price target raised to $70 from $68 at Wells Fargo (TipRanks)
Dec-17-24 08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
Dec-11-24 06:06PM	ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma (Clinical Trials Arena)
Dec-10-24 10:30AM	Incyte Late-Breaking Tafasitamab (Monjuvi) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma (Business Wire)
Dec-09-24 04:46PM	Analyst Report: Incyte Corporation (Morningstar Research) -5.02%
Dec-07-24 07:30AM	Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer (Business Wire)
Dec-06-24 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.02%
Nov-28-24 11:31AM	Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report? (Zacks)
Nov-26-24 04:10PM	Incyte Announces Updated Presentation Time for Upcoming Investor Conference (Business Wire)
Nov-25-24 10:09AM	Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting (Business Wire)
Nov-22-24 06:01AM	Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock (Insider Monkey)
Nov-20-24 04:31PM	Analyst Report: Incyte Corporation (Morningstar Research)
Nov-19-24 04:30PM	S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing (Investopedia) -8.33%
04:02PM	Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. (Investor's Business Daily)
12:41PM	Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study (Investopedia)
12:21PM	Incyte Is the S&P 500s Worst Performer Today. Whats Hitting the Stock. (Barrons.com)
12:18PM	Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges (Benzinga)
11:30AM	Incyte Faces Challenges but Remains Focused on Strategic Growth (GuruFocus.com)
06:13AM	Incyte sinks on setback for drugs acquired in $750M buyout (BioPharma Dive)
Nov-18-24 10:40PM	Analyst Report: Incyte Corporation (Morningstar Research)
04:30PM	Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs (Business Wire)
08:28AM	Is Incyt Corporation (INCY) the Best Immunotherapy Stock to Buy Now? (Insider Monkey)
Nov-16-24 10:06AM	Heres How Jakafis Patent Expiry Impacts Incyte Corporations (INCY) Growth Prospects (Insider Monkey)
Nov-15-24 07:05PM	Analyst Report: Incyte Corporation (Morningstar Research)
Nov-14-24 08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
Nov-07-24 07:22PM	Analyst Report: Incyte Corporation (Morningstar Research)
04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-06-24 06:02AM	Bank of America Turns Bullish on These 2 Lesser-Known Stocks (TipRanks)
Nov-05-24 04:32AM	Syndax agrees funding with Royalty Pharma for Niktimvo US sales (Pharmaceutical Technology)
Oct-30-24 04:37PM	Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock (Benzinga)
08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
03:03AM	Incyte Corp (INCY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
01:05AM	Q3 2024 Incyte Corp Earnings Call (Thomson Reuters StreetEvents)
Oct-29-24 04:59PM	S&P 500 Gains and Losses Today: Ford Stock Falters as Earnings Miss the Mark (Investopedia) +12.04%
04:10PM	Incyte Breaks Out To 17-Month High As Jakafi Demand Surges (Investor's Business Daily)
12:23PM	Incyte Rallies on Strong Q3 Revenue, Jakafi Outlook Lifted (GuruFocus.com)
12:07PM	Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura (Benzinga)
09:30AM	Here's What Key Metrics Tell Us About Incyte (INCY) Q3 Earnings (Zacks)
08:15AM	Incyte (INCY) Q3 Earnings Miss Estimates (Zacks)
07:13AM	Incyte: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs (Business Wire)
Oct-24-24 02:03PM	Incyte Named One of Top 5 Companies on Science Magazines 2024 Top Employers List (Business Wire)
Oct-17-24 01:02PM	State Street Corp's Strategic Reduction in Incyte Corp Holdings (GuruFocus.com)
Oct-15-24 08:30AM	Knight Therapeutics Announces Approval of Minjuvi (tafasitamab) in Mexico (GlobeNewswire)
Oct-10-24 09:15AM	Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program (Business Wire)
Oct-08-24 08:00AM	Incyte to Report Third Quarter Financial Results (Business Wire)
Oct-07-24 11:08PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-03-24 04:30PM	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-25-24 07:00AM	Multiple Late-Breaking Data Presentations from Incytes Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress (Business Wire)
Sep-24-24 09:15AM	Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase (PR Newswire)
Sep-18-24 05:15PM	Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo (axatilimab-csfr) in Chronic Graft-Versus-Host Disease (PR Newswire)
02:44PM	Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets (Benzinga)
Sep-16-24 08:27PM	Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers (Investor's Business Daily)
Sep-14-24 12:45PM	Incytes CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer (Business Wire)
10:30AM	Incytes Retifanlimab (Zynyz) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium (Business Wire)
Sep-09-24 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-29-24 11:31AM	Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-21-24 11:40AM	Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024 (Business Wire)
Aug-17-24 01:20AM	Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug (Zacks)
Aug-16-24 10:33AM	Armed with Phase III win, Incyte eyes label expansion for Monjuvi (Pharmaceutical Technology)
Aug-15-24 04:30PM	Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi) in Relapsed or Refractory Follicular Lymphoma (Business Wire)
12:32PM	FDA greenlights Incyte and Syndaxs GvHD drug Niktimvo (Pharmaceutical Technology)
10:11AM	FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication (Benzinga)
08:08AM	Incyte builds out its arsenal of post-transplant drugs (BioPharma Dive)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Denton Sheila A.	EVP & General Counsel	Mar 04 '25	Option Exercise	58.06	599	34,778	26,447	Mar 06 04:56 PM
Denton Sheila A.	EVP & General Counsel	Mar 04 '25	Sale	69.99	599	41,924	25,848	Mar 06 04:56 PM
SHEILA DENTON	Officer	Mar 04 '25	Proposed Sale	69.99	599	41,924		Mar 04 05:12 PM
Denton Sheila A.	EVP & General Counsel	Feb 26 '25	Option Exercise	58.06	9,574	555,866	39,917	Feb 28 06:34 PM
Denton Sheila A.	EVP & General Counsel	Feb 26 '25	Sale	74.07	14,069	1,042,136	25,848	Feb 28 06:34 PM
SHEILA DENTON	Officer	Feb 26 '25	Proposed Sale	74.07	14,069	1,042,138		Feb 26 04:04 PM
Stein Steven H	EVP & Chief Medical Officer	Jan 21 '25	Sale	72.69	12,352	897,867	66,967	Jan 22 04:05 PM
STEVEN STEIN	Officer	Jan 21 '25	Proposed Sale	72.69	12,352	897,906		Jan 21 04:03 PM
Tray Thomas	Principal Accounting Officer	Dec 13 '24	Sale	70.64	650	45,916	23,962	Dec 17 12:37 PM
Tray Thomas	Principal Accounting Officer	Dec 16 '24	Sale	69.31	650	45,052	23,312	Dec 17 12:37 PM
THOMAS R TRAY	Officer	Dec 16 '24	Proposed Sale	69.31	650	45,052		Dec 16 04:04 PM
Iyengar Vijay K	EVP, GMAPPS	Nov 29 '24	Sale	75.38	6,043	455,544	30,658	Dec 03 12:52 PM
VIJAY IYENGAR	Officer	Nov 29 '24	Proposed Sale	75.39	6,043	455,555		Nov 29 01:28 PM
Flannelly Barry P	EVP & General Manager US	Nov 06 '24	Option Exercise	70.03	3,680	257,719	61,722	Nov 08 12:48 PM
Flannelly Barry P	EVP & General Manager US	Nov 06 '24	Sale	79.68	3,680	293,210	58,042	Nov 08 12:48 PM
BARRY FLANNELLY	Officer	Nov 06 '24	Proposed Sale	79.68	3,680	293,210		Nov 06 04:15 PM
Tray Thomas	Principal Accounting Officer	Sep 12 '24	Sale	62.94	572	36,002	24,825	Sep 16 01:25 PM
Tray Thomas	Principal Accounting Officer	Sep 13 '24	Sale	63.37	382	24,207	24,443	Sep 16 01:25 PM
Dickinson Jonathan Elliott	EVP, General Manager, Europe	Sep 12 '24	Sale	62.36	8,450	526,948	36,390	Sep 16 01:24 PM
THOMAS R TRAY	Officer	Sep 13 '24	Proposed Sale	63.37	382	24,207		Sep 13 04:06 PM
JONATHAN ELLIOTT DICKINSON	Officer	Sep 12 '24	Proposed Sale	62.36	8,450	526,930		Sep 12 04:17 PM
Stein Steven H	EVP & Chief Medical Officer	Aug 12 '24	Sale	60.63	11,608	703,793	90,011	Aug 14 03:37 PM
STEVEN STEIN	Officer	Aug 12 '24	Proposed Sale	60.63	11,608	703,771		Aug 12 04:39 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 25 '24	Sale	70.00	15,571	1,089,970	36,701	Jul 29 03:50 PM
Flannelly Barry P	EVP & General Manager US	Jul 16 '24	Sale	64.19	1,306	83,832	58,042	Jul 17 12:24 PM
Flannelly Barry P	EVP & General Manager US	Jul 09 '24	Sale	60.00	8,148	488,880	50,534	Jul 11 12:35 PM
Flannelly Barry P	EVP & General Manager US	Jun 12 '24	Sale	60.00	19,164	1,149,840	66,377	Jun 14 12:17 PM
Tray Thomas	Principal Accounting Officer	Jun 06 '24	Sale	58.91	1,093	64,389	21,634	Jun 10 12:25 PM
BAKER BROS. ADVISORS LP	Director	May 07 '24	Option Exercise	49.01	30,000	1,470,300	33,462,981	May 09 06:25 PM

Dollar change -11.54
Percentage change -3.42	%

MEDP Medpace Holdings Inc daily Stock Chart

Peers: IQV CRL INCY LH ICON CTLT KOD FATE ALLO ONC

| Held by: IJH VTI VB VXF VBK XMHQ MDY IBB IJK IWP

Index	-	P/E	25.79	EPS (ttm)	12.63	Insider Own	17.99%	Shs Outstand	30.56M	Perf Week	0.46%
Market Cap	9.93B	Forward P/E	23.58	EPS next Y	13.82	Insider Trans	-0.07%	Shs Float	24.99M	Perf Month	-7.97%
Income	404.34M	PEG	3.09	EPS next Q	3.06	Inst Own	84.52%	Short Float	5.86%	Perf Quarter	-4.80%
Sales	2.11B	P/S	4.71	EPS this Y	-2.33%	Inst Trans	-0.14%	Short Ratio	4.91	Perf Half Y	-2.94%
Book/sh	27.01	P/B	12.06	EPS next Y	12.01%	ROA	21.52%	Short Interest	1.46M	Perf Year	-20.45%
Cash/sh	21.97	P/C	14.83	EPS next 5Y	8.35%	ROE	58.41%	52W Range	302.01 - 459.77	Perf YTD	-1.91%
Dividend Est.	-	P/FCF	17.35	EPS past 5Y	36.50%	ROI	42.48%	52W High	-29.12%	Beta	1.42
Dividend TTM	-	Quick Ratio	0.93	Sales past 5Y	19.95%	Gross Margin	29.73%	52W Low	7.90%	ATR (14)	11.38
Dividend Ex-Date	-	Current Ratio	0.93	EPS Y/Y TTM	42.04%	Oper. Margin	21.19%	RSI (14)	43.06	Volatility	3.75% 3.29%
Employees	5900	Debt/Eq	0.18	Sales Y/Y TTM	11.84%	Profit Margin	19.17%	Recom	2.42	Target Price	356.75
Option/Short	Yes / Yes	LT Debt/Eq	0.15	EPS Q/Q	49.32%	Payout	0.00%	Rel Volume	1.50	Prev Close	337.41
Sales Surprise	0.34%	EPS Surprise	24.87%	Sales Q/Q	7.66%	Earnings	Feb 10 AMC	Avg Volume	298.02K	Price	325.87
SMA20	-2.56%	SMA50	-4.37%	SMA200	-9.58%	Trades		Volume	441,203	Change	-3.42%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-23-24	Downgrade	Robert W. Baird	Outperform → Neutral	$413 → $349
Oct-14-24	Initiated	Redburn Atlantic	Buy
Sep-27-24	Downgrade	UBS	Buy → Neutral	$420 → $350
Sep-25-24	Downgrade	Jefferies	Buy → Hold	$415 → $345
Aug-01-24	Initiated	Truist	Hold	$415
May-29-24	Initiated	TD Cowen	Buy	$452
May-28-24	Initiated	Mizuho	Buy	$435
Apr-23-24	Upgrade	Jefferies	Hold → Buy	$340 → $450
Mar-18-24	Initiated	Deutsche Bank	Hold	$395
Feb-15-24	Upgrade	UBS	Neutral → Buy	$282 → $452
Oct-24-23	Upgrade	Robert W. Baird	Neutral → Outperform	$270 → $289
May-08-23	Upgrade	Guggenheim	Neutral → Buy	$252
Oct-27-22	Upgrade	UBS	Sell → Neutral	$142 → $238
Sep-07-22	Initiated	UBS	Sell	$142
May-24-22	Initiated	Guggenheim	Neutral
Aug-05-21	Resumed	Credit Suisse	Outperform	$205
Oct-02-20	Upgrade	Truist	Hold → Buy	$124 → $135
Jun-08-20	Upgrade	Robert W. Baird	Underperform → Neutral	$83
May-13-20	Downgrade	Wolfe Research	Outperform → Peer Perform
Apr-30-20	Upgrade	SunTrust	Sell → Hold	$85

Show Previous Ratings

Mar-03-25 04:04AM	2 Reasons to Watch MEDP and 1 to Stay Cautious (StockStory)
Feb-17-25 08:55AM	Here are the Reasons to Invest in Medpace Holdings (MEDP) (Insider Monkey)
Feb-14-25 08:00AM	Medpace Holdings, Inc. (MEDP): A Bull Case Theory (Insider Monkey)
Feb-12-25 09:12AM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research)
02:08AM	Medpace Holdings Inc (MEDP) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
12:06AM	Loading…
12:06AM	Q4 2024 Medpace Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-11-25 11:54AM	Why Medpace (MEDP) Shares Are Trading Lower Today (StockStory) -7.52%
Feb-10-25 04:39PM	Medpace: Q4 Earnings Snapshot (Associated Press Finance)
04:33PM	Medpace (NASDAQ:MEDP) Posts Q4 Sales In Line With Estimates But Stock Drops (StockStory)
04:15PM	Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results (Business Wire)
Feb-09-25 08:03AM	Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-07-25 08:14AM	Here are Giverny Capital Asset Managements Updates on Medpace Holdings (MEDP) (Insider Monkey)
Jan-20-25 08:55AM	What Makes Medpace Holdings (MEDP) a Promising Investment? (Insider Monkey)
Jan-03-25 08:27AM	Lower than Expected Results Dragged Medpace Holdings (MEDP) in Q3 (Insider Monkey)
Jan-02-25 04:05PM	Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 10, 2025 (Business Wire)
06:52PM	Loading…
Nov-21-24 06:52PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research)
Nov-15-24 06:47PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research) -7.23%
Nov-06-24 06:36PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research) +9.15%
Nov-04-24 10:12AM	What Makes Medpace Holdings (MEDP) a Good Holding? (Insider Monkey)
Nov-01-24 07:33PM	Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Medpace Holdings, Inc. for potential violations of securities laws (GlobeNewswire)
Oct-29-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Aviat, Medpace, Customers Bancorp, and Ibotta and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-23-24 03:56AM	Q3 2024 Medpace Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Oct-22-24 05:42PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research) -7.47%
04:04PM	How Medpace Just Blew Up Expectations For Double-Digit Sales Growth In 2025 (Investor's Business Daily)
10:09AM	Medpace Stock Drop. Biotechs Doldrums Are to Blame. (Barrons.com)
Oct-21-24 04:25PM	Medpace: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Medpace Holdings, Inc. Reports Third Quarter 2024 Results (Business Wire)
Oct-16-24 11:23AM	Medpace Holdings (MEDP) Reveals "Shocking" Bookings Miss, Shares Fall - Hagens Berman (Newsfile)
10:44AM	LVS Advisory Increased its Investment in Medpace (MEDP) in Q3 (Insider Monkey)
Oct-10-24 01:56PM	Medpace Holdings (MEDP) Reveals Shocking Bookings Miss, Shares Fall - Hagens Berman (GlobeNewswire)
07:42AM	Loading…
07:42AM	Heres Why Medpace (MEDP) Detracted in Q3 (Insider Monkey)
Oct-08-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating MaxLinear, Centuri, Medpace, and Franklin and Encourages Investors to Contact the Firm (GlobeNewswire)
Sep-30-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Cardlytics, Medpace, Customers Bancorp, and Ibotta and Encourages Investors to Contact the Firm (GlobeNewswire)
Sep-24-24 05:26PM	Medpace Holdings, Inc. (MEDP): A Bull Case Theory (Insider Monkey) -9.90%
04:05PM	Medpace Holdings, Inc. to Report Third Quarter 2024 Financial Results on October 21, 2024 (Business Wire)
Aug-30-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Centuri, Medpace, Customers Bancorp, and Globus and Encourages Investors to Contact the Firm (GlobeNewswire)
Aug-29-24 12:40PM	Medpace Holdings (MEDP) Reveals Shocking Bookings Miss, Shares Fall - Hagens Berman (GlobeNewswire)
Aug-26-24 04:02PM	Medpace Holdings (MEDP) Reveals Shocking Bookings Miss, Shares Fall - Hagens Berman (GlobeNewswire)
Aug-19-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Dril-Quip, LPL Financial, Methode, and Medpace and Encourages Investors to Contact the Firm (GlobeNewswire)
Aug-16-24 06:45AM	Berry and Glatfelter Announce Magnera Board of Director Appointments in Connection With Proposed Merger of Berry's Health, Hygiene and Specialties Global Nonwovens and Films Business With Glatfelter (GlobeNewswire)
Aug-15-24 02:48PM	Medpace Holdings (MEDP) Reveals Shocking Bookings Miss, Shares Fall - Hagens Berman (GlobeNewswire)
Aug-12-24 10:11AM	Medpace Holdings (MEDP) Reveals Shocking Bookings Miss, Shares Fall - Hagens Berman (GlobeNewswire)
Aug-05-24 04:08PM	Medpace Holdings (MEDP) Reveals Shocking Bookings Miss, Shares Fall - Hagens Berman (GlobeNewswire)
Aug-02-24 07:46PM	Medpace Holdings (MEDP) Reveals Shocking Bookings Miss, Shares Fall - Hagens Berman (GlobeNewswire)
Jul-25-24 10:04AM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research)
Jul-24-24 01:01AM	Decoding Medpace Holdings Inc (MEDP): A Strategic SWOT Insight (GuruFocus.com) +6.88%
12:55AM	Q2 2024 Medpace Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Jul-23-24 06:24PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research) -18.27%
Jul-22-24 04:21PM	Medpace: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Medpace Holdings, Inc. Reports Second Quarter 2024 Results (Business Wire)
Jul-19-24 11:50AM	Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings (Zacks)
Jul-18-24 09:15AM	Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run? (Zacks)
Jul-12-24 06:15PM	Medpace (MEDP) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
Jul-11-24 12:00PM	Medpace (MEDP) Upgraded to Strong Buy: Here's Why (Zacks)
Jun-28-24 09:15AM	Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue? (Zacks)
Jun-27-24 06:37PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research)
Jun-26-24 06:15PM	Medpace (MEDP) Stock Sinks As Market Gains: Here's Why (Zacks)
04:05PM	Medpace Holdings, Inc. to Report Second Quarter 2024 Financial Results on July 22, 2024 (Business Wire)
Jun-18-24 06:13AM	Ranking the top ten clinical research organisations in the world (Pharmaceutical Technology)
Jun-17-24 06:15PM	Medpace (MEDP) Advances But Underperforms Market: Key Facts (Zacks)
Jun-12-24 04:00AM	Medpace Holdings (MEDP) Continues to Deliver Robust Financial Results (Insider Monkey)
Jun-10-24 06:15PM	Medpace (MEDP) Outperforms Broader Market: What You Need to Know (Zacks)
May-29-24 12:45PM	Here is Why Growth Investors Should Buy Medpace (MEDP) Now (Zacks)
May-17-24 04:17PM	Medpace Holdings Insider Sold Shares Worth $15,924,222, According to a Recent SEC Filing (MT Newswires)
May-14-24 04:25PM	Medpace Holdings Insider Sold Shares Worth $1,996,723, According to a Recent SEC Filing (MT Newswires)
May-13-24 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP) (Zacks)
May-10-24 09:40AM	Are Medical Stocks Lagging Medpace (MEDP) This Year? (Zacks)
08:58AM	Medpace Holdings (MEDP) Rose as it Reported Strong Matrices (Insider Monkey)
May-09-24 09:00AM	Medpace Holdings, Inc. (MEDP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
May-08-24 04:54PM	Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing (MT Newswires)
May-03-24 04:13PM	Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing (MT Newswires)
09:30AM	Brokers Suggest Investing in Medpace (MEDP): Read This Before Placing a Bet (Zacks)
May-01-24 04:59PM	Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing (MT Newswires)
Apr-25-24 06:37PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research)
12:45PM	Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think 'Yes' (Zacks)
Apr-24-24 10:37AM	Medpace Holdings, Inc. (NASDAQ:MEDP) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:58AM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research)
03:08AM	Medpace Holdings Inc (MEDP) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ... (GuruFocus.com)
Apr-23-24 10:35PM	Q1 2024 Medpace Holdings Inc Earnings Call (Thomson Reuters StreetEvents) +8.21%
Apr-22-24 05:31PM	Medpace Holdings Inc (MEDP) Surpasses Analyst Revenue and Earnings Projections in Q1 2024 (GuruFocus.com)
05:25PM	Medpace (MEDP) Beats Q1 Earnings Estimates (Zacks)
04:47PM	Medpace Q1 Earnings, Revenue Rise; Updates 2024 Guidance (MT Newswires)
04:24PM	Medpace: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Medpace Holdings, Inc. Reports First Quarter 2024 Results (Business Wire)
Apr-15-24 10:00AM	Medpace (MEDP) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-10-24 09:43AM	Should You Invest in Medpace (MEDP)? (Insider Monkey)
Apr-08-24 04:45PM	HTEC Index Q1 Spotlight: Medpace Shines in Process Automation Subsector (ETF Trends)
Apr-05-24 12:10PM	Will Medpace (MEDP) Beat Estimates Again in Its Next Earnings Report? (Zacks)
04:33AM	Medpace Holdings (MEDP) is Maintaining a Healthy Margin Profile (Insider Monkey)
Apr-01-24 07:16AM	Uber Leads Five Stocks Near Buy Points (Investor's Business Daily)
Mar-28-24 04:05PM	Medpace Holdings, Inc. to Report First Quarter 2024 Financial Results on April 22, 2024 (Business Wire)
Mar-23-24 09:00AM	U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies (The Wall Street Journal)
Mar-22-24 09:20AM	Should You Invest in Medpace (MEDP)? (Insider Monkey)
Mar-19-24 10:48AM	Does Medpace Holdings (MEDP) Have The Potential to Maintain Strong Growth? (Insider Monkey)
Mar-18-24 08:27AM	Insiders Are Selling These 5 Stocks in 2024 (Insider Monkey)
Mar-08-24 05:00PM	Director Ashley Keating Sells Shares of Medpace Holdings Inc (MEDP) (GuruFocus.com)
Mar-04-24 12:45PM	Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
12:00PM	Medpace (MEDP) Is Up 0.64% in One Week: What You Should Know (Zacks)
Feb-29-24 03:14AM	Director Ashley Keating Sells Shares of Medpace Holdings Inc (MEDP) (GuruFocus.com)
Feb-21-24 09:13AM	Does Medpace Holdings (MEDP) Have a Track Record of Robust Financial Performance? (Insider Monkey)

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The firm's services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. It operates through the following geographical segments: United States, Europe, Belgium, Asia-Pacific, and Other. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Troendle August J.	CEO	Mar 07 '25	Option Exercise	68.62	356,446	24,458,835	1,011,102	Mar 10 05:47 PM
EWALD STEPHEN P	General Counsel & Corp. Secy.	Feb 27 '25	Buy	326.11	2	652	13,343	Feb 28 04:39 PM
Carley Brian T	Director	Feb 24 '25	Option Exercise	42.62	8,127	346,373	30,035	Feb 26 04:18 PM
Carley Brian T	Director	Feb 24 '25	Sale	345.59	4,003	1,383,397	26,032	Feb 26 04:18 PM
Carley Brian T	Director	Feb 24 '25	Proposed Sale	345.59	4,003	1,383,385		Feb 24 12:52 PM
GEIGER JESSE J	President	Dec 06 '24	Option Exercise	32.05	15,000	480,750	36,503	Dec 10 04:24 PM
BURWIG SUSAN E	Exec. VP, Operations	Nov 19 '24	Option Exercise	32.05	7,500	240,375	65,000	Nov 21 04:40 PM
Kraft Robert O.	Director	Aug 22 '24	Option Exercise	42.62	4,353	185,525	4,873	Aug 26 04:37 PM
Kraft Robert O.	Director	Aug 23 '24	Option Exercise	42.62	3,774	160,848	4,294	Aug 26 04:37 PM
Kraft Robert O.	Director	Aug 22 '24	Sale	390.73	4,353	1,700,848	520	Aug 26 04:37 PM
Kraft Robert O.	Director	Aug 23 '24	Sale	390.73	3,774	1,474,615	520	Aug 26 04:37 PM
Kraft Robert O.	Director	Aug 22 '24	Proposed Sale	390.73	4,353	1,700,858		Aug 22 04:20 PM
Keating Ashley M.	Former Director	Aug 16 '24	Proposed Sale	387.00	769	297,603		Aug 16 04:58 PM
Keating Ashley M.	Former Director	Aug 15 '24	Proposed Sale	388.00	958	371,704		Aug 15 06:27 PM
Keating Ashley M.	Former Director	Aug 09 '24	Proposed Sale	388.29	1,403	544,767		Aug 09 03:50 PM
BURWIG SUSAN E	Exec. VP, Operations	Aug 05 '24	Option Exercise	90.65	50,000	4,532,500	57,500	Aug 07 04:22 PM
Keating Ashley M.	Former Director	Aug 06 '24	Proposed Sale	382.50	2,000	765,000		Aug 06 05:27 PM
Keating Ashley M.	Former Director	Jul 30 '24	Proposed Sale	389.69	1,300	506,600		Jul 30 01:23 PM
BURWIG SUSAN E	Exec. VP, Operations	Jun 05 '24	Sale	401.20	7,681	3,081,617	7,500	Jun 07 04:17 PM
Troendle August J.	CEO	May 28 '24	Sale	395.49	5,695	2,252,316	654,656	May 29 04:24 PM
Troendle August J.	CEO	May 24 '24	Sale	395.22	3,987	1,575,742	660,351	May 29 04:24 PM
Troendle August J.	CEO	May 22 '24	Sale	400.00	55	22,000	664,338	May 24 04:10 PM
Troendle August J.	CEO	May 20 '24	Sale	400.19	4,020	1,608,764	664,393	May 22 04:20 PM
Troendle August J.	CEO	May 15 '24	Sale	405.13	32,282	13,078,407	675,473	May 17 04:12 PM
Troendle August J.	CEO	May 16 '24	Sale	403.09	7,060	2,845,815	668,413	May 17 04:12 PM
Troendle August J.	CEO	May 10 '24	Sale	402.89	4,956	1,996,723	707,755	May 14 04:11 PM
Troendle August J.	CEO	May 08 '24	Sale	400.58	4,782	1,915,574	716,197	May 10 04:24 PM
Troendle August J.	CEO	May 09 '24	Sale	400.17	3,486	1,394,993	712,711	May 10 04:24 PM
Troendle August J.	CEO	May 07 '24	Sale	404.48	28,032	11,338,383	720,979	May 08 04:08 PM
Troendle August J.	CEO	May 06 '24	Sale	401.73	24,372	9,790,964	749,011	May 08 04:08 PM
Troendle August J.	CEO	May 01 '24	Sale	401.56	12,934	5,193,777	776,779	May 03 04:07 PM
Troendle August J.	CEO	May 02 '24	Sale	400.44	3,396	1,359,894	773,383	May 03 04:07 PM
Troendle August J.	CEO	Apr 29 '24	Sale	400.69	15,102	6,051,220	791,541	May 01 04:22 PM
Troendle August J.	CEO	Apr 30 '24	Sale	400.31	1,828	731,767	789,713	May 01 04:22 PM
BURWIG SUSAN E	Exec. VP, Operations	Mar 15 '24	Sale	403.00	102	41,106	15,181	Mar 19 05:11 PM
Keating Ashley M.	Director	Mar 14 '24	Option Exercise	84.36	500	42,180	500	Mar 18 05:10 PM
Keating Ashley M.	Director	Mar 14 '24	Sale	409.87	250	102,468	250	Mar 18 05:10 PM

Dollar change -8.49
Percentage change -4.85	%

CRL Charles River Laboratories International Inc daily Stock Chart

Peers: IQV LDOS MEDP CVS PFE ILMN BMY LH MRK

| Held by: VTI VOO VB RSP SPY IVV VBR XLV VBK IBB

Index	S&P 500	P/E	649.63	EPS (ttm)	0.26	Insider Own	1.12%	Shs Outstand	51.14M	Perf Week	1.41%
Market Cap	8.52B	Forward P/E	16.13	EPS next Y	10.33	Insider Trans	-0.77%	Shs Float	50.57M	Perf Month	1.73%
Income	15.93M	PEG	170.96	EPS next Q	2.11	Inst Own	105.05%	Short Float	5.80%	Perf Quarter	-13.01%
Sales	4.05B	P/S	2.10	EPS this Y	-8.97%	Inst Trans	1.91%	Short Ratio	2.75	Perf Half Y	-11.35%
Book/sh	67.69	P/B	2.46	EPS next Y	9.98%	ROA	0.20%	Short Interest	2.93M	Perf Year	-38.35%
Cash/sh	3.99	P/C	41.74	EPS next 5Y	3.80%	ROE	0.45%	52W Range	150.79 - 274.77	Perf YTD	-9.73%
Dividend Est.	-	P/FCF	16.99	EPS past 5Y	-47.65%	ROI	0.26%	52W High	-39.36%	Beta	1.39
Dividend TTM	-	Quick Ratio	1.13	Sales past 5Y	9.37%	Gross Margin	31.35%	52W Low	10.50%	ATR (14)	5.94
Dividend Ex-Date	-	Current Ratio	1.41	EPS Y/Y TTM	-96.95%	Oper. Margin	13.81%	RSI (14)	49.39	Volatility	4.33% 3.47%
Employees	20100	Debt/Eq	0.80	Sales Y/Y TTM	-1.92%	Profit Margin	0.39%	Recom	2.79	Target Price	176.20
Option/Short	Yes / Yes	LT Debt/Eq	0.79	EPS Q/Q	-216.39%	Payout	0.00%	Rel Volume	1.15	Prev Close	175.12
Sales Surprise	1.92%	EPS Surprise	5.24%	Sales Q/Q	-1.08%	Earnings	Feb 19 BMO	Avg Volume	1.07M	Price	166.63
SMA20	1.70%	SMA50	-1.78%	SMA200	-14.28%	Trades		Volume	1,209,678	Change	-4.85%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-25	Upgrade	Citigroup	Sell → Neutral	$155 → $175
Mar-03-25	Upgrade	Redburn Atlantic	Sell → Neutral	$188
Jan-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Jan-17-25	Downgrade	UBS	Buy → Neutral	$250 → $185
Nov-18-24	Downgrade	CLSA	Hold → Underperform	$164
Nov-07-24	Upgrade	CLSA	Underperform → Hold	$205
Oct-23-24	Initiated	CLSA	Underperform	$167
Oct-14-24	Initiated	Redburn Atlantic	Sell
Oct-07-24	Downgrade	Evercore ISI	Outperform → In-line	$225 → $190
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral	$250 → $215
Oct-01-24	Downgrade	Citigroup	Neutral → Sell	$215 → $175
Aug-08-24	Downgrade	Robert W. Baird	Outperform → Neutral	$239 → $191
Aug-08-24	Downgrade	JP Morgan	Overweight → Neutral	$270 → $205
Jun-28-24	Downgrade	Argus	Buy → Hold
Jun-07-24	Initiated	Mizuho	Neutral	$235
Jun-06-24	Initiated	Goldman	Buy	$290
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Sep-13-23	Initiated	TD Cowen	Market Perform	$212
Jul-10-23	Downgrade	Citigroup	Buy → Neutral	$260 → $225
Feb-23-23	Upgrade	Guggenheim	Neutral → Buy	$255

Show Previous Ratings

Mar-11-25 08:00AM	Charles River Laboratories to Present at Barclays Global Healthcare Conference (Business Wire)
Mar-05-25 04:01AM	Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4 (StockStory)
Feb-28-25 09:35AM	Bell Global Equities Sold Charles River Laboratories International (CRL) Due To Its Potential For On-going Risk To Earnings (Insider Monkey)
Feb-25-25 11:30AM	SGH and Charles River team up for CGMP cell banking services (Hospital Management)
08:00AM	Charles River Announces Agreement with Singapore General Hospital (Business Wire)
09:15AM	Loading…
Feb-24-25 09:15AM	Deciphering Charles River (CRL) International Revenue Trends (Zacks)
08:03AM	UFP Technologies (UFPT) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory)
Feb-20-25 02:04AM	Charles River Laboratories International Inc (CRL) Q4 2024 Earnings Call Highlights: Navigating ... (GuruFocus.com)
12:11AM	Q4 2024 Charles River Laboratories International Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-19-25 06:08PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research) +6.87%
04:58PM	Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance (Benzinga)
09:30AM	Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics (Zacks)
08:10AM	Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates (Zacks)
07:27AM	Charles River Laboratories (NYSE:CRL) Posts Better-Than-Expected Sales In Q4 (StockStory)
07:22AM	Charles River: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance (Business Wire)
Feb-18-25 08:03AM	Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow (StockStory)
Feb-17-25 09:16AM	Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics (Zacks)
Feb-12-25 10:00AM	Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-11-25 06:41PM	Charles River Laboratories International, Inc. (CRL) Expands AI-Powered Digital Pathology Collaboration with Deciphex (Insider Monkey)
08:00AM	Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions (Business Wire)
Jan-28-25 04:30PM	Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call (Business Wire)
Jan-23-25 07:16AM	Charles River downgraded to Market Perform from Outperform at William Blair (TipRanks)
Jan-21-25 09:09AM	RiverWater Partners Sustainable Value Strategy Trimmed its Investment in Charles River Laboratories (CRL) (Insider Monkey)
08:27AM	What Makes Charles River Labs (CRL) an Investment Bet? (Insider Monkey)
08:00AM	Charles River Expands Apollo Ecosystem, Offering Bespoke Client Experiences (Business Wire)
Jan-17-25 07:22AM	Charles River and Akron link to integrate cytokines into cell therapy (Pharmaceutical Technology)
Jan-16-25 08:00AM	Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform (Business Wire)
Jan-15-25 08:07PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
04:13PM	Charles River CEO reveals drop in 2025 revenue outlook at JP Morgan (Pharmaceutical Technology)
11:56AM	Loading…
Jan-14-25 11:56AM	Top Stock Movers Now: United Rentals, KB Home, Eli Lilly, and More (Investopedia) -6.34%
Jan-13-25 08:00AM	Charles River Laboratories to Present at J.P. Morgan Healthcare Conference (Business Wire)
Jan-07-25 08:00AM	Deciphex Secures $32.3M Series C to Address Global Pathology Shortage (Business Wire)
Dec-06-24 11:31AM	Why Is Charles River (CRL) Down 8.9% Since Last Earnings Report? (Zacks)
Dec-05-24 08:00AM	Charles River Introduces Global Biotech Incubator Program (Business Wire)
Dec-02-24 08:00AM	Charles River Laboratories to Present at Evercore ISI Investor Conference (Business Wire)
Nov-11-24 09:15AM	Charles River (CRL) International Revenue in Focus: Trends and Expectations (Zacks)
08:00AM	Charles River Laboratories to Present at UBS and Jefferies Conferences (Business Wire)
Nov-07-24 04:20AM	Q3 2024 Charles River Laboratories International Inc Earnings Call (Thomson Reuters StreetEvents)
02:19AM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
02:14AM	Charles River Laboratories International Inc (CRL) Q3 2024 Earnings Call Highlights: Navigating ... (GuruFocus.com)
12:02AM	Decoding Charles River Laboratories International Inc (CRL): A Strategic SWOT Insight (GuruFocus.com)
Nov-06-24 09:30AM	Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) +13.53%
08:10AM	Charles River Laboratories (CRL) Q3 Earnings and Revenues Beat Estimates (Zacks)
07:08AM	Charles River: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Charles River Laboratories Announces Third-Quarter 2024 Results (Business Wire)
Nov-04-24 09:16AM	Gear Up for Charles River (CRL) Q3 Earnings: Wall Street Estimates for Key Metrics (Zacks)
Oct-30-24 10:01AM	Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-29-24 12:10PM	Why Charles River (CRL) is Poised to Beat Earnings Estimates Again (Zacks)
Oct-21-24 07:45AM	FibroBiologics and Charles River link for chronic disease therapies manufacture (Pharmaceutical Technology)
Oct-17-24 08:00AM	Charles River Launches New Retrogenix Non-Human Protein Library (Business Wire)
Oct-16-24 04:30PM	Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call (Business Wire)
Oct-03-24 08:00AM	Charles River Provides Translational Expertise at Neuroscience 2024 (Business Wire)
Oct-02-24 08:00AM	Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease (Business Wire)
Sep-17-24 08:00AM	Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research (Business Wire)
Sep-06-24 11:31AM	Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report? (Zacks)
10:05AM	Higher Interest Environment Negatively Impacted Charles River Laboratories (CRL) (Insider Monkey)
Sep-04-24 09:21AM	Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience (PR Newswire)
Sep-03-24 04:30PM	Charles River Laboratories to Present at Baird and Morgan Stanley Conferences (Business Wire)
Aug-28-24 04:46AM	Charles River Laboratories International (CRL) Fell Due to a More Cautious Funding Environment (Insider Monkey)
Aug-19-24 06:53AM	Terumo and Charles River demonstrate effectiveness of CGT manufacturing device (Medical Device Network)
Aug-12-24 07:01PM	Insider Sale: EVP Joseph Laplume Sells Shares of Charles River Laboratories International Inc (CRL) (GuruFocus.com)
09:15AM	Why Charles River (CRL) International Revenue Trends Deserve Your Attention (Zacks)
Aug-09-24 01:49PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
Aug-08-24 06:30AM	Big Pharma Cuts R&D, Sending Shudders Through Industry (The Wall Street Journal)
01:04AM	Decoding Charles River Laboratories International Inc (CRL): A Strategic SWOT Insight (GuruFocus.com)
01:03AM	Q2 2024 Charles River Laboratories International Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-24 08:35PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research) -12.60%
05:36PM	S&P 500 Gains and Losses Today: Fortinet Stock Surges on Earnings Beat (Investopedia)
04:15PM	Charles River Labs Plummets 14% On 'Bleaker' Expectations For 2024 (Investor's Business Daily)
01:30PM	Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down (Zacks)
01:06PM	Charles River Labs Says It Expects Sales To Fall, Sending Its Stock Tumbling (Investopedia)
09:30AM	Here's What Key Metrics Tell Us About Charles River (CRL) Q2 Earnings (Zacks)
08:10AM	Charles River Laboratories (CRL) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
07:07AM	Charles River: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Charles River Laboratories Announces Second-Quarter 2024 Results (Business Wire)
Aug-05-24 09:16AM	Unlocking Q2 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics (Zacks)
Jul-30-24 07:28PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
08:00AM	Charles River Collaborates with Patient Advocacy Group, FOXG1 Research Foundation to Advance Rare Disease Gene Therapy Development (Business Wire)
Jul-24-24 08:43AM	Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings (Zacks)
08:00AM	Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery (Business Wire)
Jul-16-24 04:30PM	Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call (Business Wire) +5.11%
Jul-09-24 09:38AM	Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy (Zacks)
Jul-08-24 08:00AM	Charles River to Perform Plasmid Manufacturing for AAVantgarde (Business Wire)
Jul-05-24 09:23AM	Charles River (CRL) Could be an Apt Pick Right Now: Here's Why (Zacks)
Jun-27-24 10:23AM	Charles River's (CRL) RMS Growth Aids Amid FX Headwind (Zacks)
Jun-26-24 07:46AM	Charles River (CRL) Inks CDMO Deal With Gates Institutes (Zacks)
Jun-25-24 08:00AM	Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus (Business Wire)
Jun-18-24 08:49AM	The CRO Sector Looks Appealing, Says Goldman Sachs Here Are 2 Stocks to Consider (TipRanks)
07:53AM	Charles River (CRL) Advances in T-Cell Therapy With New Alliance (Zacks)
04:52AM	Charles River and Captain T Cell sign vector production agreement (Pharmaceutical Technology)
Jun-17-24 08:00AM	Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy (Business Wire)
Jun-11-24 08:13AM	Charles River (CRL) Partners to Reduce Animal Research Usage (Zacks)
08:00AM	Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives (Business Wire)
Jun-06-24 08:00AM	Charles River Laboratories Expands Access to CRADL Contract Vivarium Space in Somerville (Business Wire)
Jun-04-24 08:00AM	Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research (Business Wire)
Jun-03-24 08:00AM	Charles River Laboratories to Present at William Blair and Jefferies Conferences (Business Wire)
May-31-24 10:42AM	Charles River (CRL) Launches Viral Vector Tech Transfer Program (Zacks)
May-30-24 08:00AM	Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development (Business Wire)
07:17AM	Reasons to Hold Charles River (CRL) in Your Portfolio Now (Zacks)

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The Discovery and Safety Assessment segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FOSTER JAMES C	Chairman, President and CEO	Feb 20 '25	Buy	165.01	6,075	1,002,436	183,639	Feb 21 04:41 PM
Girshick Birgit	Corporate Executive VP & COO	Feb 20 '25	Buy	164.63	1,514	249,250	55,058	Feb 21 04:38 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Feb 20 '25	Sale	162.50	4,400	715,000	20,013	Feb 21 04:36 PM
Joseph LaPlume	Officer	Feb 20 '25	Proposed Sale	165.00	4,400	726,000		Feb 20 12:36 PM
WALLMAN RICHARD F	Director	Nov 07 '24	Sale	216.12	6,621	1,430,918	12,386	Nov 12 04:38 PM
WALLMAN RICHARD F	Director	Nov 07 '24	Sale	216.50	1,000	216,500	0	Nov 12 04:38 PM
WALLMAN RICHARD F	Director	Nov 07 '24	Proposed Sale	216.01	12,161	2,626,923		Nov 07 04:23 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Aug 08 '24	Sale	199.36	1,780	354,861	22,521	Aug 12 04:13 PM
Joseph LaPlume	Officer	Aug 08 '24	Proposed Sale	196.63	1,780	350,000		Aug 08 01:34 PM
FOSTER JAMES C	Chairman, President and CEO	Aug 01 '24	Sale	250.00	25,000	6,250,000	188,251	Aug 05 04:04 PM
FOSTER JAMES C	Officer	Aug 01 '24	Proposed Sale	250.00	25,000	6,250,000		Aug 01 04:07 PM
MASSARO GEORGE	Director	May 15 '24	Sale	235.62	332	78,225	5,855	May 16 04:35 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	May 10 '24	Sale	226.97	1,304	295,969	23,276	May 14 04:49 PM

Open in Screener

NOTV

Inotiv Inc

Mar 11 • 04:00PM ET

2.58

Dollar change +0.18
Percentage change 7.50	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: CRL ICON IQV MEDP CROX CERS BMRN CTLT EXEL NBIX

| Held by: VTI VXF PRFZ IWC AVSC DFAT AVUV DFAU DFAS DFUS

Index	-	P/E	-	EPS (ttm)	-4.61	Insider Own	11.16%	Shs Outstand	33.72M	Perf Week	-7.19%
Market Cap	87.38M	Forward P/E	-	EPS next Y	-1.16	Insider Trans	1.62%	Shs Float	30.09M	Perf Month	-26.50%
Income	-120.69M	PEG	-	EPS next Q	-0.64	Inst Own	25.87%	Short Float	6.51%	Perf Quarter	-35.82%
Sales	475.11M	P/S	0.18	EPS this Y	41.89%	Inst Trans	139.52%	Short Ratio	2.06	Perf Half Y	92.54%
Book/sh	5.04	P/B	0.51	EPS next Y	52.54%	ROA	-15.01%	Short Interest	1.96M	Perf Year	-67.55%
Cash/sh	1.12	P/C	2.30	EPS next 5Y	71.95%	ROE	-56.93%	52W Range	1.23 - 11.42	Perf YTD	-37.68%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-122.90%	ROI	-19.97%	52W High	-77.40%	Beta	3.90
Dividend TTM	-	Quick Ratio	1.15	Sales past 5Y	117.65%	Gross Margin	9.62%	52W Low	110.27%	ATR (14)	0.43
Dividend Ex-Date	-	Current Ratio	1.57	EPS Y/Y TTM	-257.19%	Oper. Margin	-12.07%	RSI (14)	32.44	Volatility	15.49% 12.84%
Employees	2075	Debt/Eq	2.63	Sales Y/Y TTM	-18.81%	Profit Margin	-25.40%	Recom	1.67	Target Price	6.33
Option/Short	Yes / Yes	LT Debt/Eq	2.56	EPS Q/Q	-70.32%	Payout	-	Rel Volume	0.72	Prev Close	2.40
Sales Surprise	-1.59%	EPS Surprise	-32.16%	Sales Q/Q	-11.53%	Earnings	Feb 05 AMC	Avg Volume	947.95K	Price	2.58
SMA20	-23.94%	SMA50	-35.53%	SMA200	-2.79%	Trades		Volume	682,562	Change	7.50%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-24	Downgrade	Jefferies	Buy → Hold	$11.50 → $3.75
Feb-09-24	Upgrade	Jefferies	Hold → Buy	$3 → $11.50
Jul-20-23	Initiated	Wells Fargo	Overweight	$9
Jan-19-23	Downgrade	Jefferies	Buy → Hold	$10 → $8
Jan-11-23	Upgrade	Lake Street	Hold → Buy	$4 → $10
Nov-18-22	Downgrade	Lake Street	Buy → Hold	$60 → $7
Oct-04-22	Initiated	Jefferies	Buy	$27
Jan-31-22	Initiated	Lake Street	Buy	$60
Sep-20-21	Initiated	Craig Hallum	Buy	$45

Feb-06-25 02:14AM	Inotiv Inc (NOTV) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... (GuruFocus.com) -6.22%
Feb-05-25 04:05PM	Inotiv Reports First Quarter Financial Results for Fiscal 2025 and Provides Business Update (GlobeNewswire) -7.01%
Jan-22-25 04:05PM	Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025 (GlobeNewswire)
Dec-30-24 04:05PM	Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million (GlobeNewswire) -11.06%
Dec-23-24 04:05PM	Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million (GlobeNewswire) +14.97%
08:00AM	Loading…
Dec-18-24 08:00AM	Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares (GlobeNewswire) -28.83%
Dec-17-24 04:03PM	Inotiv, Inc. Launches Proposed Public Offering of Common Shares (GlobeNewswire)
Dec-04-24 02:00AM	Inotiv Inc (NOTV) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Operational Challenges (GuruFocus.com) -6.21%
Dec-03-24 04:05PM	Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire) +7.44%
Dec-02-24 07:02AM	Inotiv Inc (NOTV) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +6.56%
Nov-21-24 08:30AM	Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500 (GlobeNewswire) +6.23%
Nov-20-24 04:05PM	Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024 (GlobeNewswire) +15.05%
Nov-07-24 08:00AM	Inotiv, Inc. to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences (GlobeNewswire) +8.23%
Oct-09-24 05:54PM	Inotiv Inc (NOTV) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... (GuruFocus.com)
Sep-16-24 08:00AM	Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity (GlobeNewswire) +18.97%
04:05PM	Loading…
Aug-28-24 04:05PM	Inotiv to Participate in the 8th Annual Lake Street Best Ideas Growth Conference (GlobeNewswire) +9.29%
Aug-08-24 06:15PM	Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +5.66%
04:05PM	Inotiv Reports Third Quarter Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire)
Jul-25-24 08:00AM	Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024 (GlobeNewswire)
Jul-09-24 06:50AM	3 Breakout Stocks to Buy Before They Make Headlines (InvestorPlace)
Jul-01-24 10:20AM	3 Undervalued Stocks Primed for a 2X Return (InvestorPlace)
Jun-10-24 07:30AM	Inotiv, Inc. Provides Business Updates (GlobeNewswire) +6.43%
Jun-03-24 02:49PM	Company that bred beagles for research pleads guilty to neglect, ordered to pay record $35M fine (Associated Press Finance) +16.04%
01:24PM	Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility (GlobeNewswire)
May-23-24 04:15PM	Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences (GlobeNewswire)
May-15-24 09:54PM	NOTV Stock Earnings: Inotiv Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace) +5.66%
04:05PM	Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire)
May-14-24 08:19AM	Why Is Inotiv (NOTV) Stock Down 35% Today? (InvestorPlace) -49.16%
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Wednesday, May 15, 2024 (GlobeNewswire)
05:20AM	Loading…
May-10-24 05:20AM	Inotiv Delays Release of Fiscal Q2 Results (MT Newswires) -9.62%
May-09-24 06:56PM	Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results (GlobeNewswire) -12.42%
Apr-29-24 04:05PM	Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Friday, May 10, 2024 (GlobeNewswire) -7.65%
Apr-03-24 08:50AM	Inotiv (NOTV) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Apr-02-24 08:50AM	Why Fast-paced Mover Inotiv (NOTV) Is a Great Choice for Value Investors (Zacks)
Mar-25-24 09:40AM	Is Inotiv (NOTV) a Great Value Stock Right Now? (Zacks)
Mar-18-24 08:50AM	Here's Why Momentum in Inotiv, Inc. (NOTV) Should Keep going (Zacks)
Mar-12-24 04:42PM	Rocket Stocks: 3 Picks That Could Skyrocket Your Portfolio by 2025 (InvestorPlace) +9.96%
Mar-07-24 04:20PM	3 Stocks That Could Fast-Track Your Millionaire Status (InvestorPlace) +6.54%
12:00PM	Inotiv, Inc. (NOTV) is a Great Momentum Stock: Should You Buy? (Zacks)
08:50AM	Despite Fast-paced Momentum, Inotiv, Inc. (NOTV) Is Still a Bargain Stock (Zacks)
Mar-01-24 09:40AM	Should Value Investors Buy Inotiv (NOTV) Stock? (Zacks) +7.25%
Feb-29-24 08:50AM	Here's What Could Help Inotiv, Inc. (NOTV) Maintain Its Recent Price Strength (Zacks) +13.57%
Feb-27-24 01:34PM	3 Overlooked Stocks with Potential for 500% Growth by 2025 (InvestorPlace)
Feb-20-24 07:38AM	Millionaire-Makers: 3 Game-Changing Stocks Ready for Historic Gains (InvestorPlace) +6.52%
Feb-19-24 08:50AM	Inotiv, Inc. (NOTV) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
Feb-14-24 09:40AM	Are Investors Undervaluing Inotiv (NOTV) Right Now? (Zacks) +10.23%
Feb-09-24 08:25AM	Inotiv, Inc. (NASDAQ:NOTV) Q1 2024 Earnings Call Transcript (Insider Monkey) +15.35%
Feb-08-24 09:55AM	Inotiv Inc (NOTV) Reports Revenue Growth and Reduced Net Loss in Q1 FY 2024 (GuruFocus.com) +16.85%
08:54AM	Q1 2024 Inotiv Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-07-24 06:10PM	Inotiv, Inc. (NOTV) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire)
Jan-29-24 04:05PM	Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024 (GlobeNewswire) -5.22%
Jan-27-24 09:00AM	Big Pharmas great lab monkey shortage: A crackdown on smuggling is causing chaos in Americas vital drug development pipeline (Fortune)
Dec-16-23 03:01PM	Insider Buying: COO John Beattie Acquires 47,966 Shares of Inotiv Inc (NOTV) (GuruFocus.com)
Dec-15-23 08:50AM	Inotiv, Inc. (NOTV) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Dec-14-23 08:14AM	Inotiv, Inc. (NASDAQ:NOTV) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.32%
Dec-12-23 07:45AM	Q4 2023 Inotiv Inc Earnings Call (Thomson Reuters StreetEvents) -15.84%
Dec-11-23 09:54PM	NOTV Stock Earnings: Inotiv Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.36%
04:05PM	Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update (GlobeNewswire)
Dec-06-23 04:30PM	Inotiv, Inc. Announces Plan to Insource North American Transportation Operations (GlobeNewswire) +14.55%
Nov-27-23 04:05PM	Inotiv, Inc. to Report Fiscal 2023 Fourth Quarter and Full Year Results and Host Conference Call on Monday, December 11, 2023 (GlobeNewswire) -13.73% +6.12%
Nov-13-23 04:05PM	Inotiv Provides Business Updates and Upcoming Investor Conferences Update (GlobeNewswire) +16.48%
Nov-08-23 07:30AM	Inotiv Ranked Number 127 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 (GlobeNewswire)
Nov-01-23 08:00AM	Inotiv, Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-16-23 08:00AM	Inotiv, Inc. Announces Changes to its Board Composition (GlobeNewswire) +21.95%
Aug-29-23 06:47PM	Inotiv Announces the Sale of its Israeli Businesses to Harlan Holdings Ltd. (GlobeNewswire)
Aug-24-23 04:05PM	Inotiv, Inc. to Participate in Upcoming September 2023 Investor Conferences (GlobeNewswire) -6.55%
Aug-15-23 03:31PM	Inotiv Faces SEC Probe on Imports of Monkeys From Asia (The Wall Street Journal) -6.86%
Aug-10-23 06:15PM	Inotiv, Inc. (NOTV) Q3 Earnings Miss Estimates (Zacks) -35.63%
04:08PM	Inotiv Reports Third Quarter Financial Results for Fiscal 2023 and Provides Business Update (GlobeNewswire)
Jul-24-23 04:35PM	Inotiv, Inc. to Report Fiscal 2023 Third Quarter Financial Results and Host Conference Call on Thursday, August 10, 2023 (GlobeNewswire) -5.76%
Jul-20-23 08:24PM	Strength Seen in Inotiv, Inc. (NOTV): Can Its 34.5% Jump Turn into More Strength? (Zacks) +34.52%
Jun-30-23 08:44AM	Are Options Traders Betting on a Big Move in Inotiv (NOTV) Stock? (Zacks)
Jun-05-23 09:55AM	Does Inotiv, Inc. (NOTV) Have the Potential to Rally 185.14% as Wall Street Analysts Expect? (Zacks)
May-30-23 08:50AM	Here Is Why Bargain Hunters Would Love Fast-paced Mover Inotiv, Inc. (NOTV) (Zacks)
May-25-23 08:33AM	Inotiv, Inc. to Present at Jefferies 2023 Healthcare Conference (GlobeNewswire)
May-19-23 08:33AM	Inotiv, Inc. to Participate in May Investor Conferences (GlobeNewswire)
May-18-23 09:55AM	Wall Street Analysts Predict a 168.98% Upside in Inotiv, Inc. (NOTV): Here's What You Should Know (Zacks)
May-13-23 08:15AM	Inotiv Second Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-11-23 05:55PM	Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -11.13%
04:05PM	Inotiv, Inc. Announces Second Quarter Fiscal 2023 Financial Results (GlobeNewswire)
May-08-23 08:18AM	Inotiv's (NASDAQ:NOTV) investors will be pleased with their splendid 235% return over the last five years (Simply Wall St.) +8.05%
06:27AM	4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains? (Zacks)
May-04-23 08:33AM	Inotiv, Inc. Expands Safety Pharmacology Offering to Include Cardiopulmonary Telemetry (GlobeNewswire)
Apr-26-23 08:33AM	Inotiv, Inc. to Report Fiscal 2023 Second Quarter Financial Results and Host Conference Call on Thursday, May 11, 2023 (GlobeNewswire)
Apr-11-23 09:00AM	Inotiv Applauded by Frost & Sullivan as Key Competitor in the Bio-analytical Testing Services Market (PR Newswire) +7.23%
07:27AM	Great news for Inotiv, Inc. (NASDAQ:NOTV): Insiders acquired stock in large numbers last year (Simply Wall St.)
Mar-24-23 08:38AM	Implied Volatility Surging for Inotiv (NOTV) Stock Options (Zacks)
Mar-22-23 03:45AM	Heres Why Inotiv (NOTV) Declined in Q4 (Insider Monkey)
Mar-15-23 07:00AM	Inotiv, Inc.'s (NASDAQ:NOTV) 20% loss last week hit both individual investors who own 40% as well as institutions (Simply Wall St.) +5.07%
Mar-03-23 05:30AM	Monkey Business Threatens U.S. Drug Discovery (The Wall Street Journal)
Feb-27-23 06:50AM	Daily Vickers Top Buyers & Sellers for 02/27/2023 (Argus Research) +6.82%
Feb-22-23 03:23AM	Heres Why Inotiv (NOTV) Declined in Q4 (Insider Monkey)
Feb-14-23 04:45PM	Inotiv, Inc. (NASDAQ:NOTV) Q1 2023 Earnings Call Transcript (Insider Monkey) +7.00%
Feb-13-23 04:05PM	Inotiv, Inc. Announces First Quarter Fiscal 2023 Financial Results (GlobeNewswire)
Feb-06-23 10:45PM	Inotiv, Inc. to Report Fiscal 2023 First Quarter Financial Results and Host Conference Call on Monday, February 13, 2023 (GlobeNewswire)
Feb-01-23 01:15PM	Inotiv Selected as a Winner of the 2023 Top Workplaces USA Award (GlobeNewswire) +6.21%
Jan-23-23 04:40PM	Inotiv, Inc. Announces Changes to Board of Directors (GlobeNewswire) +7.27%
Jan-12-23 12:29PM	Inotiv, Inc. (NASDAQ:NOTV) Q4 2022 Earnings Call Transcript (Insider Monkey)

Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Freeman Jeffrey Brennan	VP-Finance & Corp. Controller	Feb 18 '25	Sale	4.04	1,339	5,416	27,478	Feb 20 04:34 PM
Taylor Beth	Chief Financial Officer	Feb 18 '25	Sale	4.01	4,370	17,507	108,368	Feb 20 04:33 PM
Sagartz John E	Chief Strategy Officer	Feb 18 '25	Sale	3.94	2,113	8,316	707,816	Feb 20 04:33 PM
Leasure Robert Jr.	President and CEO	Feb 18 '25	Sale	3.82	73,617	281,136	956,592	Feb 20 04:32 PM
Leasure Robert Jr.	President and CEO	Jan 31 '25	Sale	4.15	22,700	94,298	1,030,209	Feb 04 04:15 PM
Taylor Beth	Chief Financial Officer	Jan 31 '25	Sale	4.46	2,054	9,171	112,738	Feb 04 04:14 PM
Sagartz John E	Chief Strategy Officer	Jan 31 '25	Sale	4.48	2,118	9,479	709,929	Feb 04 04:13 PM
Krupp Jeffrey Arthur	Chief Human Resources Officer	Jan 31 '25	Sale	4.48	2,036	9,123	29,029	Feb 04 04:12 PM
Krupp Jeffrey Arthur	Chief Human Resources Officer	Feb 03 '25	Sale	4.18	472	1,973	28,557	Feb 04 04:12 PM
Landman David	Director	Dec 19 '24	Buy	4.25	23,529	99,998	176,851	Dec 23 09:47 PM
Beattie John Gregory	Chief Operating Officer	Dec 10 '24	Buy	4.75	30,000	142,500	161,761	Dec 12 06:46 PM
Brown Nigel	Director	Dec 10 '24	Buy	4.26	7,500	31,950	65,537	Dec 10 04:13 PM
Harrington Michael J	Director	Dec 06 '24	Buy	3.98	10,000	39,822	37,500	Dec 10 08:34 AM
Landman David	Director	Dec 06 '24	Buy	4.14	100,000	414,000	153,322	Dec 10 08:31 AM

Open in Screener

OABI

OmniAb Inc

Mar 11 • 04:00PM ET

3.12

Dollar change -0.13
Percentage change -4.00	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ONC EBS FOLD KURA MGNX ADAP XBIT ONCT

| Held by: VTI IWM VXF IWN SCHA VTWO DFAT DFAS VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-0.62	Insider Own	19.05%	Shs Outstand	120.22M	Perf Week	-6.87%
Market Cap	377.56M	Forward P/E	-	EPS next Y	-0.37	Insider Trans	-0.79%	Shs Float	97.96M	Perf Month	-13.33%
Income	-63.02M	PEG	-	EPS next Q	-0.10	Inst Own	53.98%	Short Float	8.13%	Perf Quarter	-19.38%
Sales	20.41M	P/S	18.50	EPS this Y	-7.60%	Inst Trans	-0.57%	Short Ratio	14.93	Perf Half Y	-21.41%
Book/sh	2.43	P/B	1.29	EPS next Y	32.57%	ROA	-17.43%	Short Interest	7.96M	Perf Year	-44.29%
Cash/sh	0.49	P/C	6.36	EPS next 5Y	23.76%	ROE	-20.45%	52W Range	3.10 - 5.72	Perf YTD	-11.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-20.21%	52W High	-45.45%	Beta	-0.04
Dividend TTM	-	Quick Ratio	4.62	Sales past 5Y	13.92%	Gross Margin	-2.46%	52W Low	0.64%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	4.62	EPS Y/Y TTM	-111.80%	Oper. Margin	-402.81%	RSI (14)	33.59	Volatility	5.12% 4.41%
Employees	106	Debt/Eq	0.08	Sales Y/Y TTM	-68.45%	Profit Margin	-308.78%	Recom	1.00	Target Price	9.62
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-1.52%	Payout	-	Rel Volume	0.84	Prev Close	3.25
Sales Surprise	-50.39%	EPS Surprise	-16.36%	Sales Q/Q	-23.83%	Earnings	Mar 18 AMC	Avg Volume	533.63K	Price	3.12
SMA20	-11.51%	SMA50	-9.52%	SMA200	-21.85%	Trades		Volume	450,541	Change	-4.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$6
Apr-21-23	Initiated	The Benchmark Company	Buy	$8
Apr-13-23	Initiated	Craig Hallum	Buy	$10
Feb-22-23	Initiated	Cowen	Outperform	$10
Feb-13-23	Initiated	H.C. Wainwright	Buy	$11
Dec-20-22	Initiated	Truist	Buy	$10
Dec-16-22	Initiated	Credit Suisse	Outperform	$13
Nov-29-22	Initiated	SVB Leerink	Outperform	$6
Nov-28-22	Initiated	Stifel	Buy	$12

Feb-24-25 08:00AM	OmniAb to Report Fourth Quarter 2024 Financial Results on March 18 (Business Wire)
Feb-03-25 04:57PM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-16-24 04:15PM	OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering and Therapeutics Conference (Business Wire)
04:15PM	OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference (Business Wire)
Nov-12-24 04:05PM	OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire) -9.35%
08:00AM	Loading…
Oct-30-24 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Oct-22-24 08:00AM	OmniAb to Report Third Quarter 2024 Financial Results on November 12 (Business Wire)
Aug-26-24 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-08-24 04:05PM	OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.67%
Jul-25-24 08:00AM	OmniAb to Report Second Quarter 2024 Financial Results on August 8 (Business Wire)
Jun-03-24 04:05PM	OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology (Business Wire)
May-20-24 08:05AM	OmniAb to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-15-24 04:05PM	OmniAb Presents High-Throughput Single B-cell Screening xPloration Data at the 20th Annual PEGS Boston Summit (Business Wire)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-09-24 08:56PM	OABI Stock Earnings: OmniAb Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	Loading…
04:05PM	OmniAb Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
May-01-24 08:00AM	OmniAb to Participate in Five Investor Conferences in May (Business Wire)
Apr-22-24 08:00AM	OmniAb to Report First Quarter 2024 Financial Results on May 9 (Business Wire)
Mar-21-24 11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.17%
Mar-20-24 08:54PM	OABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Feb-28-24 08:27AM	OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-24 08:00AM	OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 (Business Wire)
Feb-20-24 08:00AM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-14-23 04:30PM	OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference (Business Wire)
Nov-20-23 12:39PM	OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 05:03AM	Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares (GuruFocus.com) +6.32%
Nov-09-23 05:55PM	OmniAb Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at Todays Research & Technology Virtual Event (Business Wire)
09:24AM	OmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net Loss (GuruFocus.com)
08:00AM	OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
08:00AM	Loading…
Nov-02-23 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Nov-01-23 09:00AM	OmniAb Appoints Steve Love to its Board of Directors (Business Wire)
Oct-31-23 04:28PM	OmniAb Announces Agenda for its Research & Technology Virtual Event (Business Wire)
Oct-26-23 02:32PM	7 of the Best Cheap Stocks to Buy Under $5 in October 2023 (InvestorPlace)
Oct-12-23 08:00AM	OmniAb to Hold Research & Technology Virtual Event on November 9 (Business Wire)
Sep-05-23 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-15-23 05:20AM	OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-13-23 08:06AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-10-23 04:05PM	OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire) -5.54%
Aug-07-23 04:05PM	OmniAb Announces the Passing of Director Sunil Patel (Business Wire)
Jul-31-23 08:00AM	OmniAb to Report Second Quarter 2023 Financial Results on August 10 (Business Wire)
Jul-17-23 07:35AM	With 60% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big guns (Simply Wall St.)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +6.32%
May-18-23 05:09PM	7 Stocks to Buy for Their Massive Upside Potential (InvestorPlace)
May-17-23 04:05PM	OmniAb Launches OmniDeep at the PEGS Boston Conference and Expo (Business Wire)
May-16-23 06:06AM	President of OmniAb Matthew Foehr Buys 22% More Shares \ (Simply Wall St.) +9.12%
May-14-23 08:03AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 10:55PM	Q1 2023 OmniAb Inc Earnings Call (Thomson Reuters StreetEvents) +8.36%
07:00AM	OmniAb Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-05-23 07:14AM	OmniAb, Inc.'s (NASDAQ:OABI) Share Price Matching Investor Opinion (Simply Wall St.)
May-04-23 06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
May-01-23 08:00AM	OmniAb to Report First Quarter 2023 Financial Results on May 11 (Business Wire)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-25-23 08:00AM	OmniAb to Participate in Upcoming Investor Conferences in May (Business Wire)
Apr-19-23 08:30AM	Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today (Zacks)
Apr-07-23 10:24PM	OmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-05-23 06:09AM	OmniAb Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Apr-02-23 08:51AM	Insiders of OmniAb, Inc. (NASDAQ:OABI) are up 11% on their US$2.3m purchase after OmniAb, Inc. (NASDAQ:OABI) rose 14% last week (Simply Wall St.)
Mar-31-23 08:40AM	Do Options Traders Know Something About OmniAb (OABI) Stock We Don't? (Zacks)
Mar-30-23 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Business Wire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-09-23 08:00AM	OmniAb to Report Fourth Quarter 2022 Financial Results on March 30 (Business Wire) -5.03%
Mar-08-23 09:53AM	These 2 Strong Buy Penny Stocks Are Poised for a Massive Rally, Say Analysts (TipRanks)
Feb-23-23 07:49AM	Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up (Zacks)
Feb-07-23 08:00AM	OmniAb to Participate in Three Upcoming Investor Conferences (Business Wire)
Feb-01-23 06:56AM	With 44% stake, OmniAb, Inc. (NASDAQ:OABI) seems to have captured institutional investors' interest (Simply Wall St.)
Dec-16-22 12:39PM	Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says (Benzinga)
Dec-01-22 08:47AM	Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies (HSB-1940) against PD-1, by combining Quatramers with OmniAbs Picobodies, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets (GlobeNewswire) -5.37%
Nov-15-22 07:00AM	OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights (Business Wire) -10.00%
Nov-03-22 08:00AM	OmniAb to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-02-22 07:00AM	OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell (Business Wire) -60.65%
Nov-01-22 04:01PM	OmniAb Announces Completion of Spin-Off and Business Combination (Business Wire) -9.26%
04:01PM	Ligand Announces Completion of OmniAb Spin-Off (Business Wire)

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 16 '25	Option Exercise	0.00	13,541	0	213,466	Feb 19 08:51 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 19 '25	Sale	3.67	7,255	26,626	206,211	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 19 '25	Sale	3.67	19,522	71,646	3,779,160	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 18 '25	Sale	3.68	13,964	51,388	3,798,682	Feb 19 08:51 PM
Berkman Charles S	Chief Legal Officer	Feb 18 '25	Sale	3.68	8,215	30,231	364,131	Feb 19 08:50 PM
Berkman Charles S	Chief Legal Officer	Feb 19 '25	Sale	3.67	7,255	26,626	356,876	Feb 19 08:50 PM
GUSTAFSON KURT A	Officer	Feb 19 '25	Proposed Sale	3.68	5,188	19,092		Feb 18 08:36 PM
FOEHR MATTHEW W	Officer	Feb 18 '25	Proposed Sale	3.68	13,964	51,390		Feb 18 08:30 PM
Berkman Charles S	Officer	Feb 18 '25	Proposed Sale	3.68	8,215	30,232		Feb 18 08:28 PM
Berkman Charles S	Chief Legal Officer	Jan 21 '25	Sale	3.24	25,489	82,584	343,190	Jan 22 05:41 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Jan 21 '25	Sale	3.24	15,526	50,304	212,720	Jan 22 05:40 PM
FOEHR MATTHEW W	President and CEO	Jan 21 '25	Sale	3.24	41,811	135,468	3,749,639	Jan 22 05:40 PM
FOEHR MATTHEW W	Officer	Jan 21 '25	Proposed Sale	3.24	41,811	135,378		Jan 21 07:25 PM
Berkman Charles S	Officer	Jan 21 '25	Proposed Sale	3.24	25,489	82,529		Jan 21 07:24 PM
GUSTAFSON KURT A	Officer	Jan 21 '25	Proposed Sale	3.24	15,526	50,271		Jan 21 07:22 PM
Berkman Charles S	Chief Legal Officer	Dec 09 '24	Sale	4.13	8,022	33,131	323,385	Dec 10 04:47 PM
FOEHR MATTHEW W	President and CEO	Dec 09 '24	Sale	4.13	13,634	56,308	3,714,447	Dec 10 04:44 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 09 '24	Sale	4.13	23,871	98,587	200,661	Dec 10 04:41 PM
GUSTAFSON KURT A	Officer	Dec 09 '24	Proposed Sale	4.13	23,871	98,476		Dec 09 08:49 PM
FOEHR MATTHEW W	Officer	Dec 09 '24	Proposed Sale	4.13	13,634	56,245		Dec 09 08:45 PM
Berkman Charles S	Officer	Dec 09 '24	Proposed Sale	4.13	8,022	33,094		Dec 09 08:41 PM
FOEHR MATTHEW W	President and CEO	Nov 25 '24	Option Exercise	3.73	99,434	370,702	3,698,600	Nov 26 04:41 PM
Avista Capital Managing Member	10% Owner	Jun 29 '24	Option Exercise	3.35	66,668	223,338	15,992,372	Jul 02 05:00 PM
FOEHR MATTHEW W	President and CEO	Jun 27 '24	Option Exercise	3.73	59,659	222,416	3,599,166	Jun 27 04:55 PM
FOEHR MATTHEW W	President and CEO	May 24 '24	Buy	4.42	240,000	1,059,840	3,536,665	May 28 05:55 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 08 '24	Sale	5.27	6,954	36,648	176,697	Apr 09 06:38 PM
Berkman Charles S	Chief Legal Officer	Apr 08 '24	Sale	5.27	6,954	36,648	292,617	Apr 09 06:37 PM
GUSTAFSON KURT A	Executive VP, Finance & CFO	Apr 01 '24	Sale	5.46	11,849	64,696	170,110	Apr 02 06:30 PM
FOEHR MATTHEW W	President and CEO	Mar 27 '24	Option Exercise	3.72	243,613	907,023	3,152,416	Mar 29 04:52 PM
FOEHR MATTHEW W	President and CEO	Mar 22 '24	Buy	5.19	225,000	1,167,750	2,908,803	Mar 25 07:07 AM

IQV IQVIA Holdings Inc daily Stock Chart

Peers: CROX MEDP LH ICON CTLT CRL INCY

| Held by: VTI VOO VO SPY IVV VTV VOT XLV IBB RSP

Index	S&P 500	P/E	24.48	EPS (ttm)	7.50	Insider Own	0.84%	Shs Outstand	176.10M	Perf Week	-0.05%
Market Cap	32.35B	Forward P/E	13.85	EPS next Y	13.25	Insider Trans	0.09%	Shs Float	174.83M	Perf Month	-11.85%
Income	1.37B	PEG	2.55	EPS next Q	2.64	Inst Own	94.11%	Short Float	2.01%	Perf Quarter	-8.23%
Sales	15.40B	P/S	2.10	EPS this Y	6.75%	Inst Trans	-1.38%	Short Ratio	2.45	Perf Half Y	-24.52%
Book/sh	34.45	P/B	5.33	EPS next Y	11.49%	ROA	5.13%	Short Interest	3.51M	Perf Year	-29.05%
Cash/sh	10.45	P/C	17.55	EPS next 5Y	9.58%	ROE	22.55%	52W Range	179.28 - 261.72	Perf YTD	-6.63%
Dividend Est.	-	P/FCF	15.30	EPS past 5Y	50.90%	ROI	7.12%	52W High	-29.89%	Beta	1.43
Dividend TTM	-	Quick Ratio	0.84	Sales past 5Y	7.04%	Gross Margin	27.66%	52W Low	2.34%	ATR (14)	5.66
Dividend Ex-Date	-	Current Ratio	0.84	EPS Y/Y TTM	2.46%	Oper. Margin	14.73%	RSI (14)	38.31	Volatility	3.40% 2.75%
Employees	88000	Debt/Eq	2.39	Sales Y/Y TTM	2.95%	Profit Margin	8.91%	Recom	1.46	Target Price	244.86
Option/Short	Yes / Yes	LT Debt/Eq	2.18	EPS Q/Q	-5.02%	Payout	0.00%	Rel Volume	1.17	Prev Close	188.78
Sales Surprise	0.78%	EPS Surprise	0.35%	Sales Q/Q	2.35%	Earnings	Feb 06 BMO	Avg Volume	1.43M	Price	183.48
SMA20	-3.90%	SMA50	-7.06%	SMA200	-15.33%	Trades		Volume	1,671,942	Change	-2.81%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-03-25	Downgrade	BTIG Research	Buy → Neutral
Dec-20-24	Initiated	Stephens	Overweight	$250
Oct-14-24	Initiated	Redburn Atlantic	Buy
Sep-04-24	Initiated	RBC Capital Mkts	Outperform	$275
Jul-24-24	Downgrade	Jefferies	Buy → Hold	$266 → $242
Jun-06-24	Initiated	Goldman	Buy	$270
Feb-26-24	Initiated	Leerink Partners	Outperform	$290
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Feb-13-24	Initiated	BTIG Research	Buy	$285
Nov-02-23	Downgrade	Robert W. Baird	Outperform → Neutral	$248 → $202
Sep-06-23	Initiated	HSBC Securities	Buy	$260
Mar-17-23	Initiated	Truist	Buy	$265
Dec-06-22	Initiated	Cowen	Outperform	$251
Nov-17-22	Downgrade	Citigroup	Buy → Neutral	$275 → $245
Aug-25-22	Initiated	Credit Suisse	Outperform	$300
Jul-15-22	Initiated	SVB Leerink	Outperform	$256
May-24-22	Initiated	Guggenheim	Buy	$244
Apr-29-22	Upgrade	Piper Sandler	Neutral → Overweight	$231 → $255
Apr-25-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$235
Aug-05-21	Resumed	Credit Suisse	Outperform	$272

Show Previous Ratings

Mar-10-25 09:00AM	IQVIA recognized as a leader in IDC MarketScapes 2024 assessment for decentralized clinical trial technologies and consulting services (Business Wire)
Mar-04-25 09:00AM	IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials (Business Wire)
Feb-25-25 09:40AM	IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Feb-24-25 09:00AM	IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence (Business Wire)
Feb-21-25 09:00AM	IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025 (Business Wire)
10:06AM	Loading…
Feb-20-25 10:06AM	IQVIA Releases 2024 Sustainability Report (Business Wire)
Feb-14-25 09:15AM	IQVIA (IQV) International Revenue Performance Explored (Zacks)
Feb-12-25 08:03AM	West Pharmaceutical Services (WST) Q4 Earnings Report Preview: What To Look For (StockStory)
Feb-07-25 03:36PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
02:15AM	IQVIA Holdings Inc (IQV) Q4 2024 Earnings Call Highlights: Record Free Cash Flow and Strategic ... (GuruFocus.com)
02:08AM	Q4 2024 IQVIA Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-06-25 09:30AM	Here's What Key Metrics Tell Us About IQVIA (IQV) Q4 Earnings (Zacks)
08:10AM	IQVIA Holdings (IQV) Beats Q4 Earnings and Revenue Estimates (Zacks)
08:08AM	IQVIA (NYSE:IQV) Exceeds Q4 Expectations, Stock Soars (StockStory)
07:17AM	IQVIA: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance (Business Wire)
Feb-05-25 08:10AM	IQVIA (IQV) Q4 Earnings Report Preview: What To Look For (StockStory)
Feb-04-25 11:00AM	IQVIA named to the Fortune Worlds Most Admired Companies list, ranked No. 1 in its sector for fourth consecutive year (Business Wire)
09:40AM	Here's Why IQVIA Holdings (IQV) is a Strong Value Stock (Zacks)
Feb-03-25 09:50AM	IQVIA Holdings (IQV) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
09:16AM	Unlocking Q4 Potential of IQVIA (IQV): Exploring Wall Street Estimates for Key Metrics (Zacks)
Jan-30-25 03:55AM	IQVIA Holdings Inc. (IQV): Driving Healthcare Advancements with NVIDIA AI Collaboration (Insider Monkey)
Jan-21-25 04:15PM	IQVIA to Announce Fourth-Quarter and Full-Year 2024 Results on February 6, 2025 (Business Wire)
Jan-17-25 09:50AM	Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock (Zacks)
Jan-16-25 09:40AM	Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term (Zacks)
Jan-15-25 12:10PM	Will IQVIA (IQV) Beat Estimates Again in Its Next Earnings Report? (Zacks)
10:34AM	IQVIA Holdings (IQV) Fell Due to Reduced Near-Term Outlook in its R&D Solutions (Insider Monkey)
Jan-13-25 02:12PM	Why Tech Stocks Are Dropping Monday (Investopedia)
09:00AM	JP Morgan 2025: NVIDIA partners with IQVIA, Illumina and Mayo Clinic (Pharmaceutical Technology)
09:00AM	IQVIA and NVIDIA Collaborate to Transform Healthcare and Life Sciences Through Advanced Agentic AI Solutions (Business Wire)
10:19AM	Loading…
Dec-23-24 10:19AM	IQVIA (IQV) Surges 3.0%: Is This an Indication of Further Gains? (Zacks)
08:00AM	Digital Health Tools are Expanding in Scope and Function to Aid Patient Diagnosis, Treatment and Monitoring, Says New Report from The IQVIA Institute (Business Wire)
Dec-14-24 09:00PM	The Drugs Young Bankers Use to Get Through the Dayand Night (The Wall Street Journal)
Dec-04-24 10:55AM	A 12-Year-Olds Journey Into the World of Ozempic (The Wall Street Journal)
Dec-03-24 12:41AM	Sanofi to Invest $1.05 Billion in New Insulin Manufacturing Base in China (The Wall Street Journal)
Nov-06-24 04:15PM	IQVIA CFO Ron Bruehlman to Speak at the UBS Global Healthcare Conference on November 13, 2024 (Business Wire)
Nov-05-24 07:11AM	Iqvia price target lowered to $265 from $280 at Morgan Stanley (TipRanks)
Nov-04-24 09:15AM	Interpreting IQVIA (IQV) International Revenue Trends (Zacks)
Nov-01-24 02:27PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
03:10AM	IQVIA Holdings Inc (IQV) Q3 2024 Earnings Call Highlights: Strong EPS Growth Amid Market Challenges (GuruFocus.com)
01:04AM	Decoding IQVIA Holdings Inc (IQV): A Strategic SWOT Insight (GuruFocus.com)
12:45AM	Q3 2024 IQVIA Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Oct-31-24 08:30PM	IQVIA (IQV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:15AM	IQVIA Holdings (IQV) Q3 Earnings and Revenues Beat Estimates (Zacks)
07:13AM	IQVIA: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	IQVIA Reports Third-Quarter 2024 Results and Announces Investor Day (Business Wire)
Oct-30-24 09:42AM	IQVIA Holdings Inc. (IQV): Among UBS Top Tech Based Disruptive Stocks For 2030 (Insider Monkey)
Oct-28-24 09:16AM	Seeking Clues to IQVIA (IQV) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Oct-24-24 10:01AM	IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth (Zacks) -7.27%
Oct-15-24 04:15PM	IQVIA to Announce Third-Quarter 2024 Results on October 31, 2024 (Business Wire)
Oct-04-24 09:40AM	Here's Why IQVIA Holdings (IQV) is a Strong Value Stock (Zacks)
Oct-02-24 09:00AM	IQVIA Announces IQVIA AI Assistant, Powered by IQVIA Healthcare-grade AI (Business Wire)
Sep-25-24 06:20PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
08:26AM	IQVIA Holdings Inc. (IQV): Hedge Funds Are Bullish On This Trending AI Stock Right Now (Insider Monkey)
Sep-19-24 09:00AM	IQVIA AI Solution Receives 2024 Frost & Sullivan Global Customer Value Leadership Award (Business Wire)
Sep-17-24 09:40AM	Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term (Zacks)
01:12AM	IQVIA Holdings Inc. (NYSE:IQV): A Non-Tech Stock With Long-Term Investment Potential (Insider Monkey)
Sep-13-24 01:41PM	Goldman Thinks IQVIA Holdings Inc. (IQV) Is A Long-Term AI Stock Set To Rally Eventually (Insider Monkey)
Sep-12-24 09:50AM	Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term (Zacks)
Sep-04-24 02:23PM	Contract Research Giant IQVIA's Data Assets Are Biggest Differentiator, Provides Best Exposure To AI And Data Opportunities: Analyst (Benzinga)
09:00AM	Signant Health expands availability of its eClinical solutions by joining IQVIA One Home for Sites initiative (PR Newswire)
Aug-29-24 06:24PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
Aug-21-24 04:15PM	IQVIA CFO Ron Bruehlman to Speak at the Morgan Stanley Annual Global Healthcare Conference on September 4, 2024 (Business Wire)
11:30AM	IQVIA (IQV) Up 3.4% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-16-24 10:09AM	Here's Why You Should Retain IQVIA (IQV) Stock for Now (Zacks)
Aug-14-24 09:45AM	How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates (GlobeNewswire)
Jul-31-24 04:13PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
Jul-29-24 09:15AM	Understanding IQVIA (IQV) Reliance on International Revenue (Zacks)
Jul-25-24 06:18PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
Jul-24-24 03:26AM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
Jul-23-24 09:40AM	Here's Why IQVIA Holdings (IQV) is a Strong Value Stock (Zacks)
01:49AM	Q2 2024 IQVIA Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
01:00AM	Decoding IQVIA Holdings Inc (IQV): A Strategic SWOT Insight (GuruFocus.com)
Jul-22-24 06:30PM	Compared to Estimates, IQVIA (IQV) Q2 Earnings: A Look at Key Metrics (Zacks) +9.20%
04:28PM	Iqvia Bolts Higher After A Surprise Segment Beat Saved Its Second Quarter (Investor's Business Daily)
01:47PM	IQVIA Stock Pops After It Beats Q2 Earnings Estimates (Investopedia)
11:25AM	IQVIA (IQV) Surpasses Earnings & Revenue Estimates in Q2 (Zacks)
10:37AM	IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings (Benzinga)
08:15AM	IQVIA Holdings (IQV) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:11AM	IQVIA: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	IQVIA Reports Second-Quarter 2024 Results (Business Wire)
Jul-17-24 11:00AM	IQVIA (IQV) to Report Q2 Earnings: What's in the Offing? (Zacks)
Jul-16-24 06:28PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
Jul-12-24 06:02AM	Will IQVIA Holdings (IQV) Bounce Back? (Insider Monkey)
Jul-11-24 08:30AM	IQVIA Named a Leader in Medical Affairs and Regulatory Operations by Everest Group (Business Wire)
Jul-08-24 04:15PM	IQVIA to Announce Second-Quarter 2024 Results on July 22, 2024 (Business Wire)
Jul-01-24 08:01AM	Clinical Development Expertise Aids IQVIA (IQV), Costs High (Zacks)
Jun-25-24 08:00AM	IQVIAs SmartSolve eQMS Wins 2024 MedTech Breakthrough Award Best Use of Artificial Intelligence in Healthcare (Business Wire)
Jun-18-24 08:49AM	The CRO Sector Looks Appealing, Says Goldman Sachs Here Are 2 Stocks to Consider (TipRanks)
06:13AM	Ranking the top ten clinical research organisations in the world (Pharmaceutical Technology)
Jun-13-24 12:23PM	IQVIA (IQV) Announces Launch of Trial Technology Platform (Zacks)
04:32AM	IQVIA introduces new trial technology platform for research sites (Clinical Trials Arena)
Jun-12-24 08:00AM	IQVIA Launches One Home Clinical Trial Technology Platform Solves Challenges and Reduces Overload at Sites (Business Wire)
Jun-10-24 08:00AM	IQVIA Institute: Innovative Therapies and Strong Pipeline to Combat Rise in Cancer Diagnoses (Business Wire)
Jun-06-24 03:07PM	Final Trades: Amazon, Goldman Sachs, AbbVie and IQVIA Holdings (CNBC TV)
Jun-03-24 06:28PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
May-28-24 06:04AM	Analysis-Weight-loss drug forecasts jump to $150 billion as supply grows (Reuters)
May-24-24 11:17AM	Here's Why You Should Hold on to IQVIA (IQV) Stock for Now (Zacks)
May-14-24 08:00AM	U.S. Medicines Spending Grew in 2023 as Greater Access Offset COVID-19-related Decline, Says IQVIA Institute (Business Wire)
May-09-24 04:15PM	IQVIA CFO Ron Bruehlman to Speak at the Bank of America Health Care Conference on May 14, 2024 (Business Wire)

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BOUSBIB ARI	See Remarks	Feb 10 '25	Option Exercise	65.16	40,000	2,606,400	837,083	Feb 12 05:11 PM
DANHAKL JOHN G	Director	Dec 03 '24	Buy	200.58	1,275	255,740	1,275	Feb 07 07:03 PM
Sherbet Eric	See Remarks	Aug 27 '24	Sale	246.33	1,300	320,229	19,536	Aug 29 05:02 PM
Sherbet Eric	Officer	Aug 27 '24	Proposed Sale	246.33	1,300	320,229		Aug 27 05:23 PM

Open in Screener

MXCT

MaxCyte Inc

Mar 11 • 04:00PM ET

3.47

Dollar change +0.05
Percentage change 1.46	%

Healthcare • Medical Devices • USA • NASD

Peers: NTLA CRSP EDIT SGMO BEAM CRBU CDXS ABCL ALLO

| Held by: VTI IWM VXF IWN VTWO IBB VHT IWC DFAS AVSC

Index	RUT	P/E	-	EPS (ttm)	-0.34	Insider Own	7.71%	Shs Outstand	105.30M	Perf Week	1.17%
Market Cap	366.02M	Forward P/E	-	EPS next Y	-0.30	Insider Trans	-1.39%	Shs Float	97.35M	Perf Month	-20.96%
Income	-35.73M	PEG	-	EPS next Q	-0.11	Inst Own	71.41%	Short Float	2.78%	Perf Quarter	-3.07%
Sales	45.60M	P/S	8.03	EPS this Y	11.73%	Inst Trans	5.76%	Short Ratio	4.89	Perf Half Y	-8.44%
Book/sh	2.03	P/B	1.71	EPS next Y	14.30%	ROA	-13.87%	Short Interest	2.70M	Perf Year	-13.68%
Cash/sh	1.46	P/C	2.38	EPS next 5Y	-	ROE	-16.00%	52W Range	3.16 - 5.26	Perf YTD	-16.59%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.20%	ROI	-15.49%	52W High	-34.03%	Beta	-
Dividend TTM	-	Quick Ratio	9.22	Sales past 5Y	18.61%	Gross Margin	76.80%	52W Low	9.64%	ATR (14)	0.22
Dividend Ex-Date	-	Current Ratio	9.81	EPS Y/Y TTM	5.99%	Oper. Margin	-101.56%	RSI (14)	34.56	Volatility	5.59% 5.61%
Employees	143	Debt/Eq	0.09	Sales Y/Y TTM	19.85%	Profit Margin	-78.36%	Recom	1.00	Target Price	7.68
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	-1.10%	Payout	-	Rel Volume	1.03	Prev Close	3.42
Sales Surprise	8.11%	EPS Surprise	16.46%	Sales Q/Q	1.99%	Earnings	Mar 11 AMC	Avg Volume	553.28K	Price	3.47
SMA20	-6.68%	SMA50	-17.50%	SMA200	-15.68%	Trades		Volume	595,715	Change	1.46%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	Craig Hallum	Buy	$7
Oct-15-21	Resumed	Cowen	Outperform
Aug-24-21	Initiated	William Blair	Outperform
Aug-24-21	Initiated	Wedbush	Outperform	$36
Aug-24-21	Initiated	Stifel	Buy	$18
Aug-24-21	Initiated	Stephens	Overweight	$19
Aug-24-21	Initiated	Cowen	Outperform
Aug-24-21	Initiated	BTIG Research	Buy	$22

Today 03:07AM	MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges (GuruFocus.com)
Mar-11-25 04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance (GlobeNewswire)
Feb-12-25 02:00AM	MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs (GlobeNewswire)
Feb-07-25 02:00AM	MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference (GlobeNewswire)
Jan-30-25 02:00AM	MaxCyte Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments (GlobeNewswire)
12:00PM	Loading…
Jan-15-25 12:00PM	All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy (Zacks)
Jan-13-25 03:05AM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) +11.59%
Dec-23-24 02:00AM	MaxCyte Announces Retirement of Board Member Art Mandell (GlobeNewswire)
Dec-09-24 02:00AM	MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance (GlobeNewswire) +15.83%
Nov-13-24 08:05AM	MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics (GlobeNewswire)
Nov-07-24 02:00PM	MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ... (GuruFocus.com) -10.82%
Nov-06-24 05:55PM	MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Oct-31-24 08:05AM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-16-24 12:00PM	MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
08:05AM	Loading…
Oct-15-24 08:05AM	MaxCyte Appoints Cynthia Collins to its Board of Directors (GlobeNewswire)
Oct-11-24 08:05AM	MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-10-24 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer (GlobeNewswire)
Oct-09-24 05:08PM	MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges (GuruFocus.com) -5.41%
Sep-17-24 03:32AM	MaxCyte and Kamau Therapeutics sign platform license agreement (Pharmaceutical Technology)
Sep-16-24 02:00AM	MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases (GlobeNewswire)
Sep-05-24 04:05PM	MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference (GlobeNewswire)
Aug-06-24 05:50PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.31%
04:05PM	MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Jul-17-24 08:50AM	MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jul-09-24 04:05PM	MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jun-13-24 09:55AM	Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect? (Zacks)
08:50AM	Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why (Zacks)
Jun-11-24 01:30AM	Insider Buying: President and CEO Maher Masoud Acquires 100,000 Shares of MaxCyte Inc (MXCT) (GuruFocus.com) -5.65%
May-29-24 08:05AM	MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference (GlobeNewswire)
08:05AM	Loading…
May-22-24 08:05AM	MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development (GlobeNewswire)
May-12-24 08:19AM	MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 02:39PM	MaxCyte Shares Rise Sharply After Q1 Results Beat (MT Newswires) +18.07%
06:35AM	Q1 2024 MaxCyte Inc Earnings Call (Thomson Reuters StreetEvents)
03:58AM	MaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
May-07-24 08:58PM	MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:45PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance (GlobeNewswire)
Apr-10-24 08:05AM	MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-02-24 08:05AM	MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) (GlobeNewswire)
Mar-14-24 08:15AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 08:17AM	11 Oversold Healthcare Stocks To Buy Right Now (Insider Monkey)
Mar-12-24 05:31PM	MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance (GlobeNewswire)
Mar-04-24 04:05PM	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results (GlobeNewswire) -12.21%
Feb-09-24 08:05AM	MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-24 08:05AM	MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugens Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers (GlobeNewswire)
Jan-23-24 08:05AM	MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs (GlobeNewswire)
Jan-08-24 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +13.73%
Jan-03-24 08:05AM	MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline (GlobeNewswire) -11.60%
Jan-02-24 02:00AM	MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director (GlobeNewswire) +6.38%
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey) +9.01%
Dec-11-23 04:05PM	MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023 (GlobeNewswire)
Dec-07-23 11:05AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Dec-02-23 09:04AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Nov-16-23 08:05AM	MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member (GlobeNewswire)
Nov-09-23 12:57PM	MaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:05PM	MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance (GlobeNewswire)
Nov-06-23 04:05PM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-05-23 12:59PM	Why Shares of MaxCyte Are Plummeting on Thursday (Motley Fool) -20.64%
08:47AM	Why Is MaxCyte (MXCT) Stock Down 21% Today? (InvestorPlace)
Oct-04-23 04:05PM	MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance (GlobeNewswire) +9.00%
Sep-06-23 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing (GlobeNewswire)
Sep-05-23 08:05AM	MaxCyte to Participate in Baird Global Healthcare Conference (GlobeNewswire)
Aug-09-23 04:05PM	MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire) -10.44%
Aug-01-23 08:05AM	MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients (GlobeNewswire)
Jul-13-23 08:05AM	MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023 (GlobeNewswire)
Jul-10-23 08:05AM	MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies (GlobeNewswire) +7.78%
Jul-08-23 04:54AM	MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 77% of the company (Simply Wall St.)
Jul-06-23 08:05AM	MaxCyte Signs Strategic Platform License with Lyell Immunopharma (GlobeNewswire)
Jun-01-23 04:05PM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.56%
May-30-23 08:18AM	Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth (Simply Wall St.)
May-14-23 03:11AM	Earnings Working Against MaxCyte, Inc.'s (LON:MXCT) Share Price Following 28% Dive (Simply Wall St.)
May-10-23 05:25PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -19.78%
04:05PM	MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire)
May-04-23 08:05AM	MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform (GlobeNewswire)
Apr-28-23 05:03AM	MaxCyte, Inc. (LON:MXCT) insider upped their holding by 400% earlier this year (Simply Wall St.)
Apr-27-23 06:36PM	7 Small-Cap Biotech Stocks with Massive Potential (InvestorPlace)
Apr-12-23 04:05PM	MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-06-23 09:30AM	The three-year returns have been strong for MaxCyte (LON:MXCT) shareholders despite underlying losses increasing (Simply Wall St.)
Mar-27-23 04:05PM	MaxCyte Appoints Douglas Swirsky as Chief Financial Officer (GlobeNewswire)
Mar-18-23 02:06AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 01:33AM	MaxCyte Full Year 2022 Earnings: US$0.23 loss per share (vs US$0.21 loss in FY 2021) (Simply Wall St.)
Mar-15-23 04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +6.43%
Mar-08-23 08:00AM	MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology (GlobeNewswire)
Mar-06-23 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance (PR Newswire) -7.55%
Feb-22-23 06:37PM	7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023 (InvestorPlace)
Feb-01-23 04:05PM	MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-29-23 03:03AM	A fantastic week for MaxCyte, Inc.'s (LON:MXCT) 70% institutional owners, one-year returns continue to impress (Simply Wall St.)
Jan-03-23 04:05PM	MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs (PR Newswire) -6.23%
Dec-21-22 09:35AM	MaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Dec-19-22 12:55PM	7 Hot Stocks to Book Profits In Before 2023 (InvestorPlace)
Dec-16-22 06:42AM	MaxCyte (LON:MXCT) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Dec-08-22 12:00PM	MaxCyte, Inc. (MXCT) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Dec-05-22 02:00AM	MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases (GlobeNewswire) -10.69%
Nov-19-22 03:18AM	Insiders who bought in the last 12 months lose an additional US$55k as MaxCyte, Inc. (LON:MXCT) drops to UK£566m (Simply Wall St.)
Nov-09-22 06:35PM	MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -9.36% +15.74%
05:35PM	MaxCyte Reports Third Quarter 2022 Financial Results (PR Newswire)
Nov-02-22 08:05AM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-23-22 07:29PM	Should You Invest in MaxCyte (MXCT)? (Insider Monkey)

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Johnston John Joseph	Director	Jan 27 '25	Option Exercise	2.93	3,000	8,796	144,950	Jan 29 04:13 PM
Johnston John Joseph	Director	Jan 27 '25	Sale	4.64	3,000	13,935	141,950	Jan 29 04:13 PM
Sandoval David I.	GENERAL COUNSEL	Jan 13 '25	Sale	4.54	4,466	20,272	41,447	Jan 14 04:03 PM
Johnston John Joseph	Director	Dec 26 '24	Option Exercise	2.93	3,000	8,796	144,950	Dec 30 04:15 PM
Johnston John Joseph	Director	Dec 26 '24	Sale	4.01	3,000	12,021	141,950	Dec 30 04:15 PM
Johnston John Joseph	Affiliate	Dec 26 '24	Proposed Sale	4.11	12,000	49,320		Dec 26 04:16 PM
Johnston John Joseph	Director	Dec 09 '24	Option Exercise	2.35	2,495	5,863	144,445	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 06 '24	Option Exercise	2.93	505	1,478	142,455	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 09 '24	Sale	3.79	2,495	9,459	141,950	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 06 '24	Sale	3.70	505	1,869	141,950	Dec 10 04:30 PM
Erck Stanley C	Director	Nov 01 '24	Option Exercise	0.04	47,689	1,908	316,807	Nov 05 04:25 PM
Erck Stanley C	Director	Nov 01 '24	Sale	3.72	47,689	177,403	269,118	Nov 05 04:25 PM
Johnston John Joseph	Director	Oct 28 '24	Option Exercise	2.93	3,000	8,778	144,950	Oct 30 04:15 PM
Johnston John Joseph	Director	Oct 28 '24	Sale	3.72	3,000	11,166	141,950	Oct 30 04:15 PM
Erck Stanley C	Director	Oct 01 '24	Option Exercise	0.04	26,082	1,043	295,200	Oct 02 05:03 PM
Erck Stanley C	Director	Oct 02 '24	Option Exercise	0.04	21,607	864	290,725	Oct 02 05:03 PM
Erck Stanley C	Director	Oct 01 '24	Sale	3.78	26,082	98,590	269,118	Oct 02 05:03 PM
Erck Stanley C	Director	Oct 02 '24	Sale	3.71	21,607	80,162	269,118	Oct 02 05:03 PM
Johnston John Joseph	Director	Sep 26 '24	Option Exercise	2.93	3,000	8,778	144,950	Sep 30 04:15 PM
Johnston John Joseph	Director	Sep 26 '24	Sale	3.82	3,000	11,460	141,950	Sep 30 04:15 PM
Johnston John Joseph	Affiliate	Sep 26 '24	Proposed Sale	3.81	9,000	34,290		Sep 26 04:11 PM
Erck Stanley C	Director	Sep 04 '24	Option Exercise	0.04	29,767	1,191	298,885	Sep 05 05:10 PM
Erck Stanley C	Director	Sep 03 '24	Option Exercise	0.04	17,922	717	287,040	Sep 05 05:10 PM
Erck Stanley C	Director	Sep 04 '24	Sale	3.97	29,767	118,175	269,118	Sep 05 05:10 PM
Erck Stanley C	Director	Sep 03 '24	Sale	4.10	17,922	73,480	269,118	Sep 05 05:10 PM
Erck Stanley C	Officer	Sep 03 '24	Proposed Sale	4.32	143,067	618,049		Sep 03 04:36 PM
Johnston John Joseph	Director	Aug 26 '24	Option Exercise	2.93	3,000	8,778	144,950	Aug 28 04:30 PM
Johnston John Joseph	Director	Aug 26 '24	Sale	4.28	3,000	12,840	141,950	Aug 28 04:30 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 02 '24	Option Exercise	1.64	17,857	29,303	42,857	Aug 05 06:57 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 01 '24	Option Exercise	1.64	15,476	25,396	40,476	Aug 05 06:57 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 02 '24	Sale	4.36	17,857	77,874	25,000	Aug 05 06:57 PM
Ross Thomas M.	EVP, GLOBAL SALES	Aug 01 '24	Sale	4.54	15,476	70,261	25,000	Aug 05 06:57 PM
Johnston John Joseph	Director	Jul 26 '24	Option Exercise	2.93	3,000	8,778	144,950	Jul 30 04:39 PM
Johnston John Joseph	Director	Jul 26 '24	Sale	4.75	3,000	14,238	141,950	Jul 30 04:39 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jul 08 '24	Option Exercise	1.64	19,802	32,495	44,802	Jul 10 04:15 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jul 09 '24	Option Exercise	1.64	13,531	22,204	38,531	Jul 10 04:15 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jul 08 '24	Sale	4.03	19,802	79,782	25,000	Jul 10 04:15 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jul 09 '24	Sale	4.03	13,531	54,584	25,000	Jul 10 04:15 PM
Johnston John Joseph	Director	Jun 27 '24	Option Exercise	2.28	10,000	22,778	151,950	Jul 01 05:18 PM
Johnston John Joseph	Director	Jun 27 '24	Sale	3.99	10,000	39,900	141,950	Jul 01 05:18 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jun 20 '24	Option Exercise	1.64	33,333	54,699	58,333	Jun 24 04:17 PM
Ross Thomas M.	EVP, GLOBAL SALES	Jun 20 '24	Sale	4.09	33,333	136,465	25,000	Jun 24 04:17 PM
Masoud Maher	President and CEO	Jun 10 '24	Buy	4.90	70,443	345,241	100,000	Jun 10 05:55 PM
Masoud Maher	President and CEO	Jun 07 '24	Buy	4.87	29,557	143,824	29,557	Jun 10 05:55 PM
Johnston John Joseph	Director	Mar 26 '24	Option Exercise	2.14	5,000	10,710	125,583	Mar 28 04:31 PM
Johnston John Joseph	Director	Mar 26 '24	Sale	4.41	5,000	22,025	120,583	Mar 28 04:31 PM

FOXO FOXO Technologies Inc daily Stock Chart

Peers: ILMN EXAS QGEN TXG ONC GH MYGN CDNA PACB TWST

Index	-	P/E	-	EPS (ttm)	-1.26	Insider Own	10.94%	Shs Outstand	31.76M	Perf Week	-0.64%
Market Cap	4.95M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	28.28M	Perf Month	-29.09%
Income	-11.44M	PEG	-	EPS next Q	-	Inst Own	1.96%	Short Float	6.67%	Perf Quarter	-68.61%
Sales	1.28M	P/S	3.87	EPS this Y	-	Inst Trans	84.45%	Short Ratio	0.25	Perf Half Y	4.00%
Book/sh	-1.29	P/B	-	EPS next Y	-	ROA	-41.36%	Short Interest	1.89M	Perf Year	-48.34%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	0.13 - 1.30	Perf YTD	-46.45%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-138.42%	52W High	-88.00%	Beta	3.37
Dividend TTM	-	Quick Ratio	-	Sales past 5Y	-1111.72%	Gross Margin	-	52W Low	20.00%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	0.08	EPS Y/Y TTM	91.91%	Oper. Margin	-585.20%	RSI (14)	37.38	Volatility	11.83% 13.77%
Employees	5	Debt/Eq	-	Sales Y/Y TTM	-52.07%	Profit Margin	-890.81%	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	79.39%	Payout	-	Rel Volume	0.23	Prev Close	0.15
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	5054.17%	Earnings	-	Avg Volume	7.45M	Price	0.16
SMA20	-15.99%	SMA50	-31.84%	SMA200	-41.57%	Trades		Volume	1,760,294	Change	1.56%

Feb-24-25 08:10AM	FOXO TECHNOLOGIES, INC. ANNOUNCES EXECUTION OF A NON-BINDING ACQUISITION AGREEMENT FOR TWO ASSISTED-LIVING FACILITIES IN FLORIDA FOR A TOTAL CONSIDERATION OF $60 MILLION (GlobeNewswire)
Jan-28-25 08:05AM	FOXO TECHNOLOGIES, INC., PROVIDES UPDATE ON RECENT ACOMPLISHMENTS AND BUSINESS STRATEGY (GlobeNewswire) -7.35%
Jan-16-25 08:30AM	FOXO TECHNOLOGIES INC., CONFIRMS DETAILS OF SPECIAL MEETING OF SHAREHOLDERS ON JANUARY 17, 2025. (GlobeNewswire) +57.97%
Jan-07-25 09:25AM	FOXO TECHNOLOGIES INC.'S BOARD OF DIRECTORS ANNOUNCES SPECIAL MEETING OF SHAREHOLDERS (GlobeNewswire)
Dec-23-24 09:25AM	FOXO TECHNOLOGIES INC. ANOUNCES DETAILS OF ITS 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 31, 2024 (GlobeNewswire)
12:32PM	Loading…
Dec-16-24 12:32PM	FOXO TECHNOLOGIES INC. ANNOUNCES THAT STOCKHOLDERS EQUITY IS GREATER THAN $4M, WHICH IS REQUIRED TO MEET THE CONTINUED LISTING REQUIREMENTS OF THE NYSE AMERICAN EXCHANGE (GlobeNewswire) -10.82%
Dec-11-24 08:00AM	FOXO TECHNOLOGIES INC. ANNOUNCES RESTRUCTURING AND CAPITAL RAISING TRANSACTIONS AND APPOINTS SEAMUS LAGAN AS CHIEF EXECUTIVE OFFICER (GlobeNewswire)
Dec-02-24 08:00AM	FOXO TECHNOLOGIES INC. ANNOUNCES RESULTS OF SPECIAL MEETING OF SHAREHOLDERS (GlobeNewswire) -11.58%
Nov-25-24 11:15AM	FOXO TECHNOLOGIES INC., CONFIRMS DETAILS OF SPECIAL MEETING OF SHAREHOLDERS ON NOVEMBER 29, 2024. (GlobeNewswire) -28.31%
08:00AM	FOXO TECHNOLOGIES INC., CONFIRMS DETAILS OF SPECIAL MEETING OF SHAREHOLDERS ON DECEMBER 29, 2024. (GlobeNewswire)
Nov-18-24 08:30AM	FOXO TECHNOLOGIES INC.'S BOARD OF DIRECTORS ANNOUNCES SPECIAL MEETING OF SHAREHOLDERS (GlobeNewswire) +6.35%
Oct-15-24 08:30AM	FOXO TECHNOLOGIES INC., PROVIDES UPDATE ON 2024 ACCOMPLISHMENTS AND PLANS FOR REMAINDER OF THE YEAR (GlobeNewswire) +6.98%
Sep-17-24 09:00AM	Foxo Technologies, Inc., Completes the Acquisition of Revenue Generating Operations From Rennova Health, Inc. (GlobeNewswire) -5.32%
Aug-08-24 08:30AM	FOXO Technologies Subsidiary, Myrtle Recovery Centers, Receives Two Full Licenses from the Tennessee Department of Mental Health and Substance Abuse Services (GlobeNewswire) -9.58%
Jul-16-24 04:30PM	FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements (GlobeNewswire)
08:30AM	Loading…
Jul-01-24 08:30AM	Foxo Technologies, Inc., Regains Compliance with SEC Reporting Requirements (GlobeNewswire) +6.55%
Jun-18-24 08:30AM	FOXO Technologies Inc. Secures Up to $2.8 Million in Senior Notes to Fund Previously Announced Acquisition of Myrtle Recovery Centers, Inc. and Provide Additional Working Capital (GlobeNewswire)
Jun-17-24 08:30AM	RENNOVA HEALTH, INC. ANNOUNCES STOCK EXCHANGE AGREEMENTS WITH FOXO TECHNOLOGIES, INC. FOR TWO OPERATING SUBSIDIARIES (GlobeNewswire) -10.93%
Jun-14-24 05:30PM	FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements; Completes Steps it Believes are Required to Regain Compliance (GlobeNewswire) +20.97%
08:30AM	FOXO Technologies Enters into Share Exchange Agreements to Acquire Healthcare Operations from Rennova Health, Inc. (GlobeNewswire)
Apr-23-24 05:00PM	FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements (GlobeNewswire)
Feb-14-24 09:32AM	FOXO Technologies Announces Non-Binding Agreement for Potentially Transformative Merger with M2i Global (GlobeNewswire) -8.50%
Jan-25-24 05:00PM	FOXO Technologies Announces Appointment of Capital Markets Veteran Francis Colt deWolf to the Board of Directors (Business Wire)
Jan-22-24 08:30AM	FOXO Technologies Formalizes License Agreement with KR8.ai to Power New Epigenetic Wellness Solutions (Business Wire) -14.49%
Dec-19-23 08:30AM	FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements (Business Wire)
Dec-01-23 09:01AM	FOXO Technologies On Track to Commence Commercial Rollout of VITHAR AI Health Coach in Early 2024 (Business Wire) +22.82%
Nov-29-23 04:30PM	FOXO Technologies Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q (Business Wire) -5.49%
Nov-10-23 08:30AM	FOXO Technologies Provides Reminder for Webinar to be Held Today, November 10th at 10 AM Eastern Time, to Unveil VITHAR AI Health Coach (Business Wire)
Nov-08-23 09:00AM	FOXO Technologies to Unveil VITHAR AI Health Coach; Schedules Webinar for Friday, November 10th at 10 AM Eastern Time (Business Wire) -21.89%
Nov-07-23 09:23AM	FOXO Technologies Expects Class A Common Stock to Resume Trading, Today, November 7, in Connection with 1-for-10 Reverse Stock Split (Business Wire) -17.53%
08:30AM	Loading…
Oct-30-23 08:30AM	FOXO Technologies Unveils Plans for New Direct-to Consumer Offering Combining the Companys Epigenetic Data with the Power of AI (Business Wire) -24.80%
Oct-27-23 05:15PM	FOXO Technologies Inc. Announces Reverse Stock Split (Business Wire) -6.99%
Oct-23-23 08:00AM	FOXO Technologies Completes Strategic Alternatives Review and Outlines Latest Progress Executing Corporate Strategy (Business Wire)
Oct-13-23 08:00AM	FOXO Technologies Announces Issue Notification from USPTO for a Patent Leveraging Machine Learning Approaches to Enable the Commercialization of Epigenetic Biomarkers (Business Wire) +8.47%
Oct-06-23 08:30AM	FOXO Technologies Interim CEO Mark White Provides Letter to Shareholders Outlining New AI-Enabled Direct-to-Consumer Strategy and Immediate Expense Reductions (Business Wire) +17.20%
Sep-06-23 08:30AM	FOXO Technologies Announces Agreement With Atrio Insurance (Business Wire) +14.48%
Aug-31-23 08:30AM	FOXO Technologies Inc. Announces NYSE American Acceptance of Compliance Plan (Business Wire) +7.97%
Aug-18-23 04:15PM	FOXO Technologies Inc. Announces Receipt of Second Notice of Non-Compliance from NYSE American (Business Wire)
Aug-17-23 08:30AM	FOXO Technologies Collaborates with DataRobot to Pave the Way for AI-Driven Epigenetic Biomarker Research in Human Longevity (Business Wire)
Aug-10-23 04:05PM	FOXO Technologies Announces Second Quarter 2023 Financial Results (Business Wire) -8.08%
Aug-08-23 08:30AM	FOXO Technologies Sets Second Quarter 2023 Business Update Call for Thursday, August 10, 2023 at 3:15 p.m. CT (Business Wire) -9.77%
Aug-07-23 08:30AM	Longevity Biotech Companies GERO and FOXO Technologies to Embark on Joint Initiative on Artificial Intelligence and Epigenetic Data to Discover Signatures of Human Health Trajectories (Business Wire) -7.98%
Jul-19-23 08:00AM	FOXO Technologies Launches Bioinformatics Services to Revolutionize Epigenetic Data Analysis (Business Wire) +19.07%
Jun-16-23 05:30AM	FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements (Business Wire) -5.02%
May-30-23 05:09PM	FOXO Technologies Announces Results of Annual Stockholders Meeting (Business Wire) +14.60%
May-17-23 04:30PM	NYSE American Has Commenced Delisting Proceedings in the FOXO WS warrants of FOXO Technologies Inc. (Business Wire) -5.97%
May-11-23 04:15PM	FOXO Technologies Announces First Quarter 2023 Financial Results (Business Wire)
Apr-18-23 08:00AM	FOXO Technologies Announces Resignation of Taylor Fay, Chief Operating Officer (Business Wire) -8.08%
08:00AM	FOXO Technologies Announces Direct-to-Consumer Launch of Longevity Report Beta Product (Business Wire)
Mar-30-23 04:05PM	FOXO Technologies Announces Full Year 2022 Financial Results and Recent Business Highlights (Business Wire) +13.51%
Mar-22-23 07:00PM	FOXO Technologies Inc. Sets Fourth Quarter and Full Year 2022 Business Update Call for Thursday, March 30, 2023 at 3:15 p.m. CT (Business Wire)
Dec-08-22 04:15PM	FOXO LIFE to Begin Distribution Relationship with AmSuisse to Sell Life Insurance Designed to Keep You Alive (Business Wire)
Nov-23-22 06:30PM	FOXO Technologies Announces Filing of Form 10-Q for the Third Quarter 2022 (Business Wire) -13.33%
Nov-15-22 12:57PM	FOXO Technologies Announces Management Changes and Delays Filing of Form 10-Q (Business Wire) -12.85%
01:24AM	FOXO Technologies Announces Departure of Chief Product Officer, Erin Sharoni (Business Wire)
Nov-14-22 04:31PM	FOXO Technologies Postpones Third Quarter 2022 Earnings Report and Conference Call (Business Wire) +6.64%
08:00AM	FOXO Technologies Announces Agreement With Haven Life (Business Wire)
Nov-07-22 04:01PM	FOXO Technologies Inc. Sets Third Quarter 2022 Earnings Call for Monday, November 14, 2022 at 3:15 p.m. CT (Business Wire)
Oct-12-22 08:00AM	FOXO Technologies Announces First Distribution Partner and Begins Product Rollout in California; Expands Executive Team With Insurance Industry Talent (Business Wire) +59.30%

FOXO Technologies, Inc. develops genetic sequencing technology, artificial intelligence and bioinformatics tools. It operates through the FOXO Labs and FOXO Life segments. The FOXO Labs segment refers to the research and development and is commercializing proprietary epigenetic biomarker technology. The FOXO Life segment is involved in combining life insurance with a dynamic molecular health and wellness platform. The company was founded in 2020 and is headquartered in Minneapolis, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Kr8 ai Inc.	10% Owner	Jul 22 '24	Sale	0.25	1,300,000	325,000	Jul 24 04:00 PM
WHITE MARK BRIAN	Interim CEO	Jul 22 '24	Sale	0.25	1,300,000	325,000	Jul 24 04:00 PM
WARD MARTIN CHRISTOPHER	Interim CFO	Jul 22 '24	Sale	0.25	1,300,000	325,000	Jul 24 04:00 PM

Open in Screener

ABSI

Absci Corp

Mar 11 • 04:00PM ET

2.95

Dollar change -0.11
Percentage change -3.59	%

Healthcare • Biotechnology • USA • NASD

Peers: INCY VRTX REGN BMRN SRPT EXEL NBIX IONS ALNY CRSP

| Held by: ARKG VTI IWM VXF IBB IWO VTWO SCHA IWN IWC

Index	RUT	P/E	-	EPS (ttm)	-0.94	Insider Own	19.15%	Shs Outstand	114.19M	Perf Week	-9.79%
Market Cap	338.82M	Forward P/E	-	EPS next Y	-0.76	Insider Trans	0.00%	Shs Float	92.86M	Perf Month	-36.83%
Income	-97.67M	PEG	-	EPS next Q	-0.22	Inst Own	63.13%	Short Float	20.53%	Perf Quarter	1.03%
Sales	4.21M	P/S	80.48	EPS this Y	28.03%	Inst Trans	1.30%	Short Ratio	3.44	Perf Half Y	-26.62%
Book/sh	1.76	P/B	1.67	EPS next Y	11.77%	ROA	-41.42%	Short Interest	19.06M	Perf Year	-42.50%
Cash/sh	1.24	P/C	2.37	EPS next 5Y	19.60%	ROE	-49.11%	52W Range	2.45 - 6.72	Perf YTD	12.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.78%	ROI	-46.88%	52W High	-56.10%	Beta	2.16
Dividend TTM	-	Quick Ratio	5.63	Sales past 5Y	37.94%	Gross Margin	-224.20%	52W Low	20.41%	ATR (14)	0.41
Dividend Ex-Date	-	Current Ratio	5.63	EPS Y/Y TTM	19.39%	Oper. Margin	-2456.69%	RSI (14)	33.34	Volatility	6.81% 10.56%
Employees	156	Debt/Eq	0.06	Sales Y/Y TTM	-39.35%	Profit Margin	-2321.56%	Recom	1.00	Target Price	8.42
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-1.13%	Payout	-	Rel Volume	0.80	Prev Close	3.06
Sales Surprise	-2.98%	EPS Surprise	-23.65%	Sales Q/Q	128.63%	Earnings	Mar 18 AMC	Avg Volume	5.54M	Price	2.95
SMA20	-30.68%	SMA50	-22.19%	SMA200	-22.44%	Trades		Volume	4,467,261	Change	-3.59%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-22-25	Initiated	Needham	Buy	$9
Oct-02-24	Initiated	Guggenheim	Buy	$10
Jul-03-24	Initiated	Morgan Stanley	Overweight	$7
Mar-14-24	Initiated	Scotiabank	Sector Outperform	$13
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight	$3
May-04-23	Initiated	H.C. Wainwright	Buy	$4
Aug-12-22	Downgrade	JP Morgan	Overweight → Underweight
Jul-18-22	Initiated	Truist	Buy	$8
Mar-02-22	Resumed	Cowen	Market Perform
Feb-01-22	Initiated	Berenberg	Buy	$28
Nov-10-21	Downgrade	BofA Securities	Neutral → Underperform	$10
Oct-15-21	Resumed	Cowen	Market Perform
Aug-16-21	Initiated	Stifel	Hold	$28
Aug-16-21	Initiated	Credit Suisse	Outperform	$40
Aug-16-21	Initiated	Cowen	Market Perform
Aug-16-21	Initiated	BofA Securities	Neutral	$26

Show Previous Ratings

Mar-04-25 04:05PM	Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025 (GlobeNewswire)
04:00PM	Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Absci to Participate in the KeyBanc Capital Markets Healthcare Forum (GlobeNewswire)
Mar-01-25 05:19PM	Why Absci Corporation (ABSI) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-18-25 08:00AM	Absci to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
09:24AM	Loading…
Feb-12-25 09:24AM	Is Absci Corp. (ABSI) the Best Nasdaq Stock Under $5 to Buy? (Insider Monkey)
Feb-11-25 09:00AM	FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape (PR Newswire) +13.39%
Jan-24-25 11:54AM	Absci Corporation (ABSI): Pioneering AI-Driven Antibody Discovery with a Buy Rating from Needham (Insider Monkey)
Jan-22-25 01:22PM	Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside (Benzinga) +25.16%
08:00AM	Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-17-25 05:58PM	Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 (PR Newswire) +11.03%
01:54PM	Absci Corporation (ABSI): AI in Biopharma Discovery (Insider Monkey)
Jan-11-25 07:40AM	Absci, Owkin announce partnership to bring together AI platforms (TipRanks)
Jan-10-25 05:48PM	Advanced Micro Devices (AMD) Invests in Absci for AI-Driven Drug Discovery with High-Performance Computing Solutions (Insider Monkey) -11.34%
07:30AM	Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery (GlobeNewswire)
01:14PM	Loading…
Jan-08-25 01:14PM	AMD Shares Slide as HSBC Downgrades Stock Over Nvidia Concerns; Absci Collaboration Announced (GuruFocus.com)
09:12AM	Absci Stock Jumps As AMD Invests $20M To Boost AI Drug Discovery (Benzinga)
07:00AM	Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery (GlobeNewswire)
06:32AM	AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips (The Wall Street Journal)
Jan-06-25 08:00AM	Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health (GlobeNewswire)
Jan-02-25 08:00AM	Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-24 02:39PM	Why Absci Corporation (ABSI) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-13-24 08:10AM	Absci highlights progress, updates across proprietary pipeline (TipRanks)
Dec-12-24 08:00AM	Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 RandD Day (GlobeNewswire) -15.98%
08:00AM	Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day (GlobeNewswire)
Nov-21-24 08:00AM	Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-20-24 09:15AM	AI's Growing Role in Transforming Healthcare Delivers Innovations in Diagnostics, Patient Care (PR Newswire)
Nov-13-24 02:07AM	Absci Corp (ABSI) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial Challenges (GuruFocus.com) -13.74%
Nov-12-24 09:23PM	Q3 2024 Absci Corp Earnings Call (Thomson Reuters StreetEvents) -14.95%
08:50AM	Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Loading…
07:30AM	Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results (GlobeNewswire)
Nov-11-24 07:15AM	Absci Corp (ABSI) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com) +5.16%
Nov-07-24 08:00AM	Absci to Host R&D Day on December 12, 2024 (GlobeNewswire)
Oct-31-24 08:00AM	Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI (GlobeNewswire) -7.25%
Oct-24-24 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-15-24 08:00AM	Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024 (GlobeNewswire)
Aug-31-24 02:37PM	Absci Corporation (ABSI): A Penny Stock That Will Make You a Millionaire (Insider Monkey)
Aug-30-24 10:30AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Aug-21-24 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 05:30PM	Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +10.99%
04:01PM	Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results (GlobeNewswire)
Aug-12-24 08:00AM	Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI (GlobeNewswire)
Jul-31-24 04:25AM	Why Is Absci Corporation (ABSI) Among the Best Micro Cap Stocks Right Now? (Insider Monkey)
Jul-10-24 08:00AM	Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024 (GlobeNewswire)
Jul-03-24 04:00PM	Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.07%
Jun-21-24 11:08AM	Is Absci Corporation (NASDAQ:ABSCI) the Best Halal Stock According to Hedge Funds? (Insider Monkey)
Jun-12-24 08:00AM	Absci to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit (GlobeNewswire) +9.98%
May-28-24 08:00AM	Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-20-24 09:32PM	Cathie Wood Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks)
May-16-24 07:15AM	7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs (InvestorPlace)
May-15-24 03:01AM	Absci Corp (ABSI) Q1 2024 Earnings Call Transcript Highlights: Strategic Advancements and ... (GuruFocus.com)
May-14-24 11:53AM	ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:30AM	Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results (GlobeNewswire)
May-12-24 03:26PM	13 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-07-24 09:13AM	Absci (ABSI) to Report Q1 Earnings: Here's What to Expect (Zacks)
Apr-16-24 08:00AM	Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024 (GlobeNewswire)
Apr-10-24 11:07AM	Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last? (Zacks) -7.67%
Mar-28-24 04:05PM	Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-23-24 05:31AM	Absci Corp (ABSI) Earnings: Misses Revenue Estimates and Reports Increased Net Loss (GuruFocus.com)
Mar-21-24 02:52PM	ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
07:30AM	Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results (GlobeNewswire)
Mar-12-24 05:34PM	11 Stocks Insiders are Buying Now (Insider Monkey) +5.11%
Mar-06-24 06:34AM	Latest Updates of Viva Biotech's Portfolio Companies (PR Newswire)
Mar-01-24 04:01PM	Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +5.81% +5.13%
06:49AM	Absci Corporation (ABSI) Surges 10.0%: Is This an Indication of Further Gains? (Zacks)
Feb-27-24 10:20PM	Absci Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	Absci Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-21-24 07:30AM	Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI (GlobeNewswire)
Feb-20-24 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.76%
Feb-05-24 09:40AM	Is Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year? (Zacks) -9.93%
Jan-10-24 07:30AM	Absci Appoints Professor Sir Mene Pangalos to its Board of Directors (GlobeNewswire) +7.06%
Jan-08-24 07:00AM	Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +15.47%
Jan-03-24 08:00AM	Absci to Participate in the 26th Annual Needham Growth Conference (GlobeNewswire)
Dec-28-23 08:00AM	Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-23 07:30AM	Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline (GlobeNewswire)
Dec-05-23 08:11AM	Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy (Zacks) +8.16%
Dec-04-23 07:30AM	Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate (GlobeNewswire) +12.64%
06:18AM	AstraZeneca inks $247M, AI-enabled oncology antibody design pact, joining Absci's list of pharma allies (FierceBiotech.com)
Dec-03-23 01:27AM	AstraZeneca, AI biologics firm Absci tie up on cancer drug (Reuters)
01:22AM	UPDATE 2-AstraZeneca, AI biologics firm Absci tie up on cancer drug (Reuters)
12:21AM	AstraZeneca ties up with AI biologics company to develop cancer drug - FT (Reuters)
12:00AM	AstraZeneca ties up with AI biologics company to develop cancer drug (Financial Times)
Nov-15-23 08:00AM	Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-14-23 06:15PM	Absci Corp (ABSI) Reports Decrease in Q3 Revenue and Lower Net Loss Year-Over-Year (GuruFocus.com) +12.00%
04:05PM	Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results (GlobeNewswire)
02:16AM	Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases (Business Wire)
Oct-26-23 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-21-23 08:00AM	Absci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan Cohen (GlobeNewswire)
Sep-06-23 08:00AM	Absci to Host R&D Day on October 4, 2023 (GlobeNewswire)
Aug-28-23 04:05PM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire) +9.82%
Aug-14-23 03:51PM	The 3 Most Undervalued Penny Stocks to Buy Now: August 2023 (InvestorPlace) +5.36%
08:02AM	Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results (GlobeNewswire)
08:00AM	Absci Appoints Zach Jonasson, Ph.D., as Chief Financial Officer and Chief Business Officer (GlobeNewswire)
Aug-10-23 08:00AM	Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development (GlobeNewswire)
Aug-01-23 08:00AM	Absci to Participate in the UBS MedTech, Tools and Genomics Summit 2023 (GlobeNewswire) -7.27%
Jul-26-23 08:00AM	Absci to Participate in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jun-15-23 08:00AM	Absci to Participate in the Morgan Stanley 2nd Annual Biotechnology AI Summit (GlobeNewswire)
Jun-07-23 09:32AM	Shareholders in Absci (NASDAQ:ABSI) are in the red if they invested a year ago (Simply Wall St.)
Jun-06-23 08:00AM	Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips (GlobeNewswire)
May-15-23 05:45PM	Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.59%

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jonasson Zachariah	CFO / CBO	Jun 13 '24	Option Exercise	3.39	28,700	97,293	404,610	Jun 14 04:40 PM
Jonasson Zachariah	CFO / CBO	Jun 13 '24	Sale	4.98	19,859	98,892	384,751	Jun 14 04:40 PM
Phoenix Venture Partners II LP	10% Owner	May 22 '24	Sale	4.40	3,100,000	13,640,000	11,279,522	May 28 01:56 PM

INCY

MEDP

CRL

NOTV

OABI

IQV

MXCT

FOXO

ABSI

Upgrade your FINVIZ experience